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ABSTRACT 
Corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) are major 
physiological stimulators of adrenocorticotropin (ACTH) secretion from the pituitary 
gland, while glucocorticoids act as inhibitors. In addition to acting alone, CRH, AVP 
and glucocorticoids interact with each other to regulate ACTH release in response to 
stress. Prolonged or repeated stimulus results in attenuated ACTH responsiveness, a 
process termed as desensitization. The aim of this study was to investigate the effects 
of interactions between CRH, AVP and steroids on desensitization of the ACTH 
response to AVP.    
         Perifused ovine anterior pituitary cells were stimulated with three 5-min pulses 
of 100 nM AVP at 120, 200 and 280 min, and were continuously exposed to CRH 
(0.2 nM) from 80 min and/or cortisol (10-500 nM) from 0 min onwards. 
Desensitization was induced by a 15 min pre-treatment with 5 nM (0.5 nM for CRH 
alone) AVP immediately preceding the second AVP pulse. When CRH was absent, 
pre-treatment with 0.5 nM AVP did not influence the ACTH response to the second 
AVP pulse. In the presence of CRH, the response to the second AVP pulse was 
reduced to 66.7±2.2% of control (n=6, P<0.0001, t-test).  
        On the other hand, following 5 nM AVP pre-treatment, continuous perifusion 
with cortisol (100 nM) results in a significantly smaller reduction in the response to 
the second AVP pulse compared with that seen in its absence (78.4±1.7% c.f. 
66.7±1.9% of control; n=10, P<0.001, t-test). In contrast to this, following 5 nM AVP 
pre-treatment, continuous CRH and cortisol in combination results in a greater 
reduction in the response to the second AVP pulse compared with that obtained in the 
absence of these two hormones (46.5±1.7% c.f. 66.2±1.7 of control; n=8, P<0.0001, 
t-test). 
         Taken together, these data suggest that desensitization of the ACTH response to 
AVP can be modulated by CRH and/or cortisol: CRH or CRH and cortisol in 
combination amplify this desensitization, whereas cortisol reduces it.  
  V  
ABBREVIATIONS 
ACTH adrenocorticotropin 
125I-OACTH 125I-labelled ovine ACTH 
ATC alkali-treated casein 
AVP arginine vasopressin 
BK channels calcium-activated potassium channels 
cAMP cyclic AMP 
CaM calmodulin 
CRH  corticotropin-releasing hormone 
CRH-R1 type 1 CRH receptor 
CSPs calcium-sensor proteins 
DAG   diacylglycerol 
DB   dispersing buffer 
ddH2O   distilled, deionized H2O 
DEX dexamethasone 
DME   Dulbecco’s modified Eagle’s medium 
DME/NCS DME + 10 % newborn calf serum 
GPCR   G protein-coupled receptor 
GR glucocorticoid receptor 
GRK G-protein coupled receptor kinase 
HPA   hypothalamo-pituitary-adrenal 
IP3   inositol 1.4.5-trisphosphate 
KR   Krebs ringer 
KR/ATC  Krebs Ringer + 0.05% ATC + 0.005% L-
ascorbate 
MR mineralocorticoid receptor 
NCS    newborn calf serum 
NS   not significant 
  Abbreviation 
 VI 
NSB   non-specific binding 
P/ATC   0.05 M phosphate buffer + 0.1% ATC 
PEG   polyethylene glycol solution 
PIP2   phosphatidylinositol 4.5-bisphosphate 
PKA  protein kinase A 
PKC  protein kinase C 
PLC phospholiphase C 
PVN paraventricular nucleus 
RIA  radioimmunoassay 
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1 
INTRODUCTION 
1.1 The Hypathalamo-Pituitary-Adrenal Axis: Regulation of 
Adrenocorticotropin Release  
To function properly, the various organs of an animal must communicate well with 
each other to maintain a constant internal environment (i.e., homeostasis) and respond 
appropriately to any changes (e.g. stressful stimuli) in the internal and external 
environments (Hiller-Sturmhofel & Bartke 1998). A key component involved in the 
vertebrate response to stress is activation of the hypothalamo-pituitary-adrenal (HPA) 
axis. As shown in Figure 1.1.1, corticotrophin (ACTH) secretion from pituitary gland 
is the central part of the HPA axis. Upon input of stressful stimuli, increased 
corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) are released 
from the hypothalamus into the pituitary portal circulation, where they stimulate 
ACTH secretion. This, in turn, triggers an increase in glucocorticoid release from the 
adrenal gland and these steroid hormones act on multiple targets to restore 
homeostasis (Buckingham et al. 1997).  
 
Regulation of ACTH secretion within the HPA axis is a multifactorial process, with 
the hypothalamic peptides CRH and AVP being important physiological stimulators, 
and adrenal glucocorticoids as a major inhibitory factor by feedback loops (Aguilera 
1994). In addition to steroid inhibition, ACTH has been shown to elicit an inhibitory 
effect on hypothalamic release of CRH/AVP, but the physiological significance of 
this is unclear (Buckingham et al. 1997). 
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Figure 1.1.1 Activation of the hypothalamo-pituitary-adrenal axis. Solid lines represent positive 
stimulation, dashed lines represent negative feedback. 
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1.1.1 Control of ACTH release by stimulators 
CRH and AVP are the most important physiological stimulators of ACTH release 
from the pituitary gland (Antoni 1993). CRH is mainly released from the 
parvocellular division of the paraventricular nucleus (PVN). About half of the CRH-
containing neurons in the PVN also contains AVP and thus release both CRH and 
AVP (Antoni 1993). AVP is also released from magnocellular neurons of the 
supraoptic and paraventricular nuclei (Antoni 1993; Scott & Dinan 1998).  It has been 
suggested that AVP from both origins is involved in stimulating ACTH secretion, 
although these two vasopressinergic systems appear to respond to different stress 
paradigms (Antoni 1993; Aguilera 1994).  
 
AVP had already been structurally characterized and implicated in the regulation of 
ACTH secretion from the anterior pituitary by the mid-1950s (Martini & Morpurgo 
1955), but this remained controversial for nearly 30 years.  Meanwhile, most studies 
focused on CRH as a potent physiological stimulator for ACTH release (Antoni 
1993). When the CRH molecule was characterized and synthetic 41-CRH became 
available in the early 1980s (Vale et al. 1981), studies using rat anterior pituitary cells 
confirmed that AVP significantly potentiates the effect of CRH on ACTH secretion, 
although vasopressin alone is a weak ACTH secretagogue in this species (Gillies et al. 
1982; Bilezikjian & Vale 1987). Studies in mouse, horse and fallow deer pituitary 
cells show that, similar to the situations in the rat, AVP is less potent in stimulating 
ACTH release than CRH in these species (Hoffman et al. 1985; Evans et al. 1993a; 
Willard et al. 1995). In contrast to this, experiments conducted in ovine anterior 
pituitary cells provide conflicting results. Whereas some studies suggest that CRH is 
more effective in stimulating ACTH release from perifused ovine anterior pituitary 
cells than AVP (Evans et al. 1988; Hassan et al. 2003), other researchers have found 
that AVP is a much more potent stimulator than CRH in ovine pituitary static cultures 
(Familari et al. 1989; Liu et al. 1990). Overall, all studies in sheep pituitary cells have 
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confirmed that AVP alone is a strong stimulus for ACTH secretion (Evans et al. 1988; 
Familari et al. 1989; Liu et al. 1990; Hassan et al. 2003). 
  
Exposure of normal sheep to various stimuli, such as insulin-induced hypoglycemia 
(Engler et al. 1989; Caraty et al. 1990), audiovisual stress (Engler et al. 1989), 
transport (Smith & Dobson 2002), and endotoxin challenge (Battaglia et al. 1998), 
result in pulsatile secretion of AVP and CRH into pituitary portal circulation, and this 
is associated with increased plasma ACTH and/or cortisol concentration. Similar 
results have been observed in horse with insulin-induced hypoglycemia (Alexander et 
al. 1996).  In addition, exogenous administration of CRH and/or AVP into normal rats 
(Tizabi & Aguilera 1992; Hauger & Aguilera 1993) and sheep (Keller-Wood 1998) 
also results in increased plasma ACTH, while immunoneutralization of AVP or CRH 
in intact sheep significantly reduced the ACTH and cortisol responses to isolation-
restraint and insulin-induced hypoglycemia (Guillaume et al. 1992a; 1992b). These 
studies, together with the in vitro results, clearly demonstrate the important 
physiological roles of AVP and CRH in stimulating ACTH release from the pituitary 
gland. 
 
In addition to individual effects on ACTH secretion, CRH and AVP exert a 
synergistic effect on ACTH response when these two secretagogues are given 
together. Extensive studies using isolated pituitary cells or segments have shown that 
the ACTH response to CRH and AVP in combination is higher than the summed 
responses to CRH or AVP alone in sheep (Evans et al. 1988; Familari et al. 1989; Liu 
et al. 1990; Kemppainen & Clark 1993), rat (Gillies et al. 1982; Bilezikjian & Vale 
1987; Watanabe & Orth 1987), horse (Evans et al. 1993a) and fallow deer (Willard et 
al. 1995). Similarly, simultaneous administration of CRH and AVP in human (Debold 
et al. 1984), rat (Rivier & Vale 1983) and sheep (McFarlane et al. 1995) significantly 
increased the amount of ACTH release to a level that is much higher than that in 
response to either CRH or AVP alone infusion. Furthermore, blockade of either 
endogenous AVP or CRH by chronic immunoneutralization markedly reduced the 
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ACTH response to infusion of the other one (Guillaume et al. 1992a; 1992b; Rivier & 
Vale 1983). Together these studies confirm a synergistic effect of CRH and AVP on 
ACTH release. 
1.1.2 Control of ACTH release by glucocorticoid inhibition 
In contrast to CRH and AVP, excessive levels of glucocorticoids inhibit the activation 
of the HPA axis by feedback loops (Keller-wood & Dallman 1984).The inhibitory 
effect of glucocorticoids on ACTH secretion at the pituitary level has been well 
established both in vivo and in vitro. Reduction in circulating steroids, such as 
following adrenalectomy, are usually associated with an increased ACTH secretion, 
which can be reversed by glucocorticoid replacement (Buckingham et al. 1997).  For 
example, lowering plasma cortisol levels by metyrapone treatment increased the 
pituitary venous concentrations of CRH, AVP and ACTH in the horse (Alexander et 
al. 1993), whereas the ACTH response to exogenous CRH and/or AVP is diminished 
by cortisol replacement in adrenalectomized sheep (McFarlane & Coghlan 1995). 
Increasing steroid levels by infusion of cortisol and corticosterone significantly 
suppressed the ACTH response to insulin injection in the dog (Keller-Wood & Bell 
1988). Consistent with this, addition of cortisol or corticosterone to the medium 
markedly reduced the ACTH response of perifused horse and sheep anterior pituitary 
cells (Evans et al. 1993b; Kemppainen & Clark 1995), and rat pituitary segments 
(Shipston & Antoni 1991), to AVP or CRH pulses. The effects of glucocorticoids are 
dose-dependent (Evans et al. 1993b; Clark & Kemppainen 1994).  Similar results 
have been observed using static culture of isolated pituitary cells (Abou-Samra et al. 
1986; Bilezikjian & Vale 1987). Taken together, it is evident that glucocorticoids play 
an important physiological role in regulating ACTH release from the pituitary gland.  
1.1.3 Control of ACTH release by interaction between CRH, AVP and 
glucocorticoids 
ACTH secretion is regulated not only by stimulatory factors such as CRH and AVP, 
and inhibitory factors such as glucocorticoid feedback, but also by a complex 
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interaction between these factors (Evans et al. 1996). Several lines of in vitro 
evidence indicate that glucocorticoid inhibition of CRH- or AVP-stimulated ACTH 
response can be overcome by the combined action of CRH and AVP (Abou-Samra et 
al. 1986; Shipston & Antoni 1992a; Evans et al. 1996; Livesey et al. 2000; Lim et al. 
2002).  For example, exposure of horse anterior pituitary cells to continuous cortisol 
(100 nM) significantly suppressed the ACTH response to successive AVP pulses. 
This inhibitory effect of cortisol was prevented by the presence of CRH perifusion 
(0.02 nM), suggesting a role of CRH in protecting AVP-stimulated ACTH secretion 
against steroid feedback (Evans et al. 1996). In adrenalectomized sheep, suppression 
of the ACTH response to CRH infusion by cortisol replacement is blocked by 
combined CRH and AVP administration (McFarlane & Coghlan 1995). The above 
data indicate the complex regulation of ACTH secretion under physiological 
conditions, where all three hormones are likely to be present. 
1.2 Molecular Mechanisms of Regulation of ACTH Secretion  
1.2.1 Actions of AVP and CRH in stimulating ACTH release 
The primary targets for AVP and CRH in the anterior pituitary are the corticotrope 
cells, where they initiate activation of different intracellular signalling pathways 
through binding to distinct receptors. The action of CRH in the pituitary corticotrope 
is mediated through binding to the type 1 CRH receptor (CRH-R1), which is a 
member of the G-protein coupled receptor (GPCR) family (Aguilera et al. 2004). 
Upon ligand binding, CRH-R1s are coupled to the Gs heterotrimeric G-protein, which 
in turn, activates adenylyl cyclase. Subsequently, cyclic AMP (cAMP) is produced as 
a second messenger, thereby stimulating protein kinase A (PKA), resulting in influx 
of extracellular Ca2+ via voltage-sensitive L- (L-VSCC) and T-type channels 
(reviewed in Antoni 1993; Mason et al. 2002).  
 
AVP binds to the V1b receptor, another member of the GPCR family. V1b receptors 
associate with the Gq/11 protein, which subsequently, stimulates the activity of 
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phospholiphase C (PLC) (Birnbaumer 2000). Activated PLC promotes hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2), generating  two intracellular second 
messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (Nishizuka 
1984; Berridge & Irvine 1984; Bilezikjian & Vale 1987). Although both of these 
intracellular messengers stimulate ACTH secretion by increasing the concentration of 
intracellular free Ca2+, the underlying mechanisms are different. IP3 mediates the 
release of Ca2+ from intracellular stores (Berridge & Irvine 1984), whereas DAG 
increases cytosolic Ca2+ through activation of protein kinase C (PKC) leading to 
influx of extracellular Ca2+ (Nishizuka 1984; Liu et al. 1990). This dual mechanism 
results in the two phases of ACTH release upon exposure to AVP: a rapid ‘spike’ 
phase dependent on release of Ca2+ from intracellular stores, followed by a sustained 
‘plateau’ phase, which requires Ca2+ influx mediated by activation of PKC (Oki et al. 
1991). 
 
It has been suggested that AVP- and CRH-triggered signalling pathways interact at 
multiple sites to potentiate the effect on ACTH secretion (Bilezikjian & Vale 1987). 
Incubation of rat anterior pituitary cells with either 10 nM AVP or 100 nM phorbol 
12-myristate 13-acetate in combination with 10 nM CRH significantly increased both 
the ACTH release and cAMP formation in response to CRH (Abou-Samra et al. 
1987). A synergistic effect on ACTH release has also been observed with application 
of 8-Br-cAMP and AVP together in rat pituitary cells (Bilezikjian & Vale 1987). 
These effects appear to be mediated by PKC-dependent inhibition of cAMP 
degradation and enhancement of adenylyl cyclase activity (Abou-Samra et al. 1987). 
Regulation of Ca2+ is implicated as another interacting site. Depletion of IP3-sensitive 
Ca2+ stores of rat anterior pituitary cells by thapsigargin pretreatment inhibits the 
ACTH response to CRH in a dose- and time-dependent manner, indicating that this 
intracellular Ca2+ store is crucial for the sustained activity of adenylyl cyclase (Won & 
Orth 1995).  
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1.2.2 Actions of glucocorticoids in regulating  ACTH release 
The effects of glucocorticoids are mediated through two types of intracellular 
cytoplasmic receptors, namely mineralocorticoid receptor (MR) and glucocorticoid 
receptor (GR; Deak et al. 1999). Although the affinity of GRs for glucocorticoids is 
lower than that of MRs, GRs are abundant in the anterior pituitary gland and are 
predominantly involved in the control of ACTH secretion (Willard et al. 1995). The 
activated receptors are translocated to nucleus, where they initiate specific changes in 
DNA transcription and therefore in protein synthesis (Buckingham et al. 1997).  
 
 Inhibition of the ACTH response to CRH and AVP by glucocorticoids falls into three 
patterns depending on the length of exposure to steroid hormones: fast (within 
seconds to minutes), intermediate (2 to 10 h) and slow (hours to days) feedback 
(Keller-Wood & Dallman 1984). These are mediated by different mechanisms. Fast 
feedback inhibits ACTH secretion very rapidly without requiring new protein 
synthesis, whereas intermediate feedback requires mRNA and protein synthesis 
(reviewed in Keller-Wood & Dallman 1984). Both fast and intermediate feedback 
inhibit ACTH release rather than synthesis, while the slow feedback appears to affect 
both ACTH release and synthesis.   
 
Most in vitro experiments looking at glucocorticoid inhibition are conducted in 
isolated pituitary tissues, and usually within the timeframe of intermediate steroid 
feedback. Multiple sites for the action of glucocorticoids have been indicated from 
those studies. One is modulation of extracellular Ca2+ influx via L-VSCC by 
glucocorticoids. Dexamethasone (DEX) pretreatment of perifused rat anterior 
pituitary cells for 2 h significantly reduced the ACTH response to CRH and the 
sustained plateau phase of the response to AVP, but had no effect on the spike phase 
of the response to AVP (Oki et al. 1991). It has been suggested that calcium-activated 
potassium (BK) channels are a primary target for glucocorticoid action in AtT20 cells 
(Shipston et al. 1996). Pretreatment with 1 µM DEX for 2 h prevented the inhibition 
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of the outward steady-state potassium current by cAMP analogue or CRH. This was 
accompanied by a significant reduction in the ACTH response to CRH. In the absence 
of PKA, no effect of DEX on mean current density was observed, indicating that DEX 
pretreatment blocked PKA-mediated inhibition of BK channels (Shipston et al. 1996). 
Additional mechanisms of glucocorticoid action include stabilization of actin 
filament, which may interfere with ACTH exocytosis (Castellino et al. 1992), and an 
action on paracrine factors (Jia et al. 1992). 
 
The inhibitory effect of glucocorticoids can be overcome by the combined action of 
CRH and AVP, as described in Section 1.1.3. Mechanisms underlying this are 
unclear. It has been suggested that the ACTH response to AVP is less sensitive to 
glucocorticoid feedback than the response to CRH (Abou-Samra et al. 1986; 
Bilezikjian & Vale 1987; Evans et al. 1993b). This is probably due to lack of 
glucocorticoid inhibition on the ACTH response to AVP-stimulated IP3 signalling 
pathway (Oki et al. 1991).  DEX treatment of normal rats for 7 days even resulted in 
significant increase in AVP-stimulated IP3 formation (Rabadan-Diehl & Aguilera 
1998). 
 
CRH and AVP have also been shown to activate the c-fos gene in mouse AtT20 cells 
and in rat aortic smooth muscle cells, respectively, which interferes with    
glucocorticoid-induced gene transcription (Nambi et al. 1989; Autelitano & Sheppard 
1993). Furthermore, both CRH and AVP are capable of regulating GRs in rat 
hippocampus and anterior pituitary (Hügin-Flores et al. 2003). All of these 
mechanisms may contribute to the regulation of ACTH secretion when CRH, AVP, 
and glucocorticoids are present.    
1.3 Desensitization of the ACTH Response to AVP  
The ACTH response to stimuli is influenced by other factors in addition to those 
already mentioned. For example, prolonged or repeated stimulus leads to attenuated 
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responsiveness, i.e. adaptation of the system. This can also be seen in vitro. Exposure 
of isolated anterior pituitary cells to repeated or prolonged CRH or AVP stimulation 
results in gradual loss of ACTH responsiveness, a process termed as desensitization.  
Under physiological conditions, this mechanism acts as a negative feedback signal to 
prevent the HPA axis from overstimulation.  
1.3.1 Desensitization of G-protein coupled receptors 
The principal function of GPCRs is to transmit extracellular information to the 
interior of cells by interacting with heterotrimeric G-proteins (Böhm et al. 1997; 
Ferguson & Caron 1998). In intact cells or tissues, exposure of GPCRs to their 
agonists usually results in a rapid loss of responsiveness, or desensitization (Lohse et 
al. 1990). GPCR desensitization plays an important physiological role by acting as a 
feedback signal limiting both acute and chronic overstimulation of GPCR signal 
transduction pathways, but it also limits the therapeutic usefulness of many 
pharmacological treatments (Ferguson & Caron 1998).  
 
Many studies of GPCR desensitization have been conducted with the β2-adrenergic 
receptor (β2AR). Although most mechanisms elucidated from studies with this 
receptor are representative, there are many subtle differences in the regulation of 
different GPCRs (Mason et al. 2002). The major mechanisms of GPCR 
desensitization include receptor uncoupling from its associated G-protein due to 
receptor phosphorylation, receptor internalization, and loss of cellular receptors due to 
degradation or reduced receptor synthesis (Ferguson 2001). Desensitization through 
the first mechanism is usually rapid, occurring within seconds to minutes of the onset 
of the stimulus. Two classes of protein kinases have been shown to be involved in 
phosphorylation of GPCRs, namely second messenger-dependent protein kinases (e.g. 
PKA and PKC) and G-protein-coupled receptor kinases (GRKs) (Ferguson 2001). 
Whereas the former class of kinases phosphorylates both agonist-occupied receptors 
and free receptors (receptors that are not bound with agonist), GRKs selectively 
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phosphorylate agonist-activated receptors (Böhm et al. 1997; Ferguson 2001). 
Consequently, two types of desensitization can be distinguished based on the above 
mechanisms, homologous and heterologous desensitization. Homologous 
desensitization, which is mediated by phosphorylation of agonist-bound receptors, 
does not affect the cellular responses to other stimuli. On the other hand, heterologous 
desensitization results from phosphorylation of both free and agonist-occupied 
receptors. It can therefore cause desensitization of more than one type of receptor 
(Lohse et al. 1990; Mason et al. 2002). In addition, GRK-mediated desensitization 
occurs much faster (e.g. t½<15 s) than that induced by second messenger-dependent 
kinases such as PKA (t½=3.5 min), suggesting that GRK-mediated desensitization 
may be most important in the regulation of receptors in rapidly changing situations 
such as the synaptic cleft (Roth et al. 1991). 
 
GPCR internalization from the cell surface to an intracellular compartment was 
initially considered as a primary factor contributing to receptor desensitization 
because it sequestrated GPCR from its effectors (Sibley & Lefkowitz 1985). This was 
subsequently reconsidered as the desensitization process is usually more rapid than 
receptor endocytosis, and pharmacological blockade of β2AR internalization did not 
affect the receptor desensitization profile (Ferguson 2001).  It is now recognized that 
GPCR internalization is often more important for receptor resensitization (cell 
recovery from desensitization) than for desensitization. This was demonstrated by the 
studies in which inhibition of endocytosis blocked resensitization of cellular 
responsiveness to agonists of the β2AR with no effect on its desensitization (reviewed 
in Böhm et al. 1997). Nevertheless, although internalization is not important for 
β2AR, receptor internalization may contribute to desensitization of some receptors by 
depleting the cell surface receptors (Böhm et al. 1997). 
 
Compared with desensitization through receptor uncoupling, receptor down-
regulation, a decrease in the total number of receptors due to long-term exposure to 
agonist (hours to days), results in a slow desensitizing process (Böhm et al. 1997). As 
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described above, down-regulation can be achieved either by a reduction of receptor 
synthesis, or degradation of existing receptors (Mason et al. 2002). 
1.3.2 Desensitization of the V1b receptor 
Regulation of the V1b receptor appears to play a critical role in most chronic stress 
paradigms as shown by the good correlation between changes in pituitary V1b 
receptor levels and pituitary corticotrope responsiveness (Aguilera & Rabadan-Diehl 
2000). For example, pituitary V1b receptor levels decreased during chronic osmotic 
stimulation, which is associated with reduced ACTH responsiveness; in contrast to 
this, stressors that results in hyper-responsiveness to a novel stress have shown an 
increased V1b receptor level (Volpi et al. 2004). Down-regulation of V1b receptors 
can also be caused by continuous AVP administration or by adrenalectomy. Chronic 
injection of AVP into normal rats reduces pituitary AVP receptor levels by ~80%, 
which is followed by decreased ACTH release (Koch & Lutz-Bucher 1985). The 
pituitary AVP binding was also decreased in adrenalectomized rats (Antoni et al. 
1985), which may be due to increased exposure of the pituitary to AVP following 
adrenalectomy (Aguilera et al. 2004).  
 
The reduction in ACTH response to repeated or prolonged stimuli, i.e. desensitization, 
can also be seen in vitro using either anterior pituitary cells or segments from different 
species. Exposure of rat anterior pituitary segments to 100 nM AVP for 4 h reduced 
the ACTH response to subsequent stimulation with either 10 or 1000 nM AVP by 
~50% and ~80% respectively, whereas the response to CRH was not affected (Holmes 
et al. 1984). Similar results have been reported by Murakami et al. (1984) and by 
Castro (1993) using rat and mouse anterior pituitary cells, respectively. Both groups 
found that pre-treatment of cells with AVP at concentrations as low as 1 nM was 
capable of eliciting a significant reduction in response to subsequent AVP application. 
AVP-induced desensitization also occurs in perifused ovine anterior pituitary cells. 
Repetitive 10-min AVP (100-2000 nM) pulses at 60 min intervals resulted in a 
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gradual loss of cellular ACTH responsiveness with time, which was defined as 
homologous desensitization to AVP as it did not reduce the response to CRH (Evans 
et al. 1988). In a more recent study (Hassan et al. 2003), a rapid AVP desensitization 
process was observed in perifused ovine anterior pituitary cells. In this study, both the 
concentration of AVP (0-20 nM) and the durations (0-25 min) used for pre-treatment 
were closely matched with endogenous AVP pulses in the sheep. It was found that 
pre-treatment with AVP for 25 min reduced the response to the subsequent 5-min 
AVP (100 nM) pulse in a dose-dependent manner, with a threshold concentration at 2 
nM (Hassan et al. 2003). The authors suggest that the rapid desensitization and 
recovery of the ACTH response to AVP is more likely to be involved in regulating the 
ACTH response to AVP during acute stress than chronic stress. A later study 
indicated that the desensitization process involved V1b receptor internalization and 
phosphorylation, as blockade of V1b internalization with concanavalin A significantly 
reduced the extent of desensitization, whereas inhibition of receptor 
dephosphorylation extended the time for cell recovery (Hassan & Mason 2005). 
Taken together, these studies suggest that V1b receptor desensitization plays an 
important role in regulating ACTH release during stress.  
 
The protein kinase(s) responsible for V1b receptor phosphorylation is unknown, but it 
has been shown that neither PKC nor casein kinase 1α is involved in this process 
(Hassan & Mason 2005). Since V1b receptor contains one proximal GRK consensus 
motif at its C terminus (Berrada et al. 2000), there is a great opportunity for GRKs 
being involved in V1b receptor phosphorylation. However, this has not so far been 
demonstrated.   
1.3.3 Influence of CRH and glucocorticoids on desensitization of the ACTH 
response to AVP 
Since interaction between CRH, AVP and glucocorticoids is known to play an 
important role in regulating ACTH secretion, one might predict that CRH and/or 
cortisol may have some effect on desensitization of the ACTH response to AVP.  
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Previously, the effect on AVP-induced ACTH desensitization of continuous 
perifusion with a low level of CRH (0.01 nM) has been tested in our laboratory 
(Hassan et al. 2003). This experiment was aimed at testing the idea that CRH acts to 
set the gain of corticotrope responsiveness to fluctuations in AVP. Although, at this 
concentration, CRH alone did not stimulate ACTH secretion, it enhanced the ACTH 
response to pulses of AVP, but it had no effect on desensitization. However, CRH at 
concentrations higher than 0.01 nM was not tested in this previously study.  
 
Other researchers have also observed possible effects of hormonal interaction on the 
AVP desensitization process. Using perifused sheep anterior pituitary cells, Evans and 
coworkers (1988) have shown that the decrease in response to repetitive AVP or CRH 
pulses (defined as desensitization of the ACTH response to AVP or CRH) was 
enhanced by the presence of AVP and CRH in combination. In perifused horse 
anterior pituitary cells, the decrease in response to successive AVP pulses (determined 
by the ratio between the responses to the sixth pulse and to the first pulse) is not 
affected by the presence of cortisol perifusion (100 nM), whereas it is greater when 
both CRH (0.02 nM) and cortisol are present, and greatest with CRH alone (Evans et 
al. 1996). In addition, the effect of CRH (1-25 pM) alone seems concentration-
dependent (Evans et al. 1993a). However, in the studies using horse anterior pituitary 
cells, the authors did not address whether the decrease in response to repeated AVP 
pulses was due to desensitization or other factors.  
 
Since V1b receptor phosphorylation and internalization have been found to be 
important in the AVP desensitization process (Hassan & Mason, 2005), the actions of 
CRH and/or glucocorticoids in regulating these two procedures may influence the 
extent of AVP-induced ACTH desensitization. No evidence to date has been found for 
the involvement of PKA in V1b receptor phosphorylation. Instead of phosphorylating 
V1b receptors, PKA has been shown to phosphorylate GRK2 (Kohout & Lefkowitz 
2003). This phosphorylation promotes the activity of GRK2, thereby enhancing 
GRK2-mediated desensitization of β2AR (Kohout & Lefkowitz 2003). It is possible 
  Introduction 
 15 
that CRH influences GRK activity through activation of PKA, which in turn, 
influences V1b receptor phosphorylation and thus desensitization. 
 
Calcium sensor proteins (CSPs), such as recoverin and calmodulin (CaM), are able to 
alter the activities of GRKs in different GPCRs (Pronin et al. 1997; Sallese et al. 
2000). DEX treatment of mouse AtT20 cells for 90 min significantly enhanced both 
CaM mRNA levels (10-fold) and protein expression (2-fold), while simultaneous 
application of CRH with DEX blocked the induction of CaM mRNA by DEX 
(Shipston & Antoni 1992b; Shipston 1995). This suggests the possibility that both 
CRH and cortisol affect the AVP desensitization process via CSPs, particularly CaM, 
acting on GRK activity. 
 
It has been shown that CRH (21 nM) significantly increases the rate of V1b receptor 
internalization within 30 min in rat anterior pituitary cells (Mogenson et al. 1988). 
However, in the same study, AVP binding to V1b receptors is not affected.  It is not 
sure whether this effect of CRH will contribute to desensitization of the ACTH 
response to AVP.  
 
Recently, actin polymerization has been reported to play a role in clathrin-mediated 
endocytosis (Kaksonen et al. 2006), which is a major pathway for GRK-induced 
GPCR internalization (Ferguson 2001). However, there are conflicting results about 
the effect of actin filaments on receptor-mediated endocytosis. Whereas some studies 
have shown that stabilization of actin filament is crucial for receptor endocytosis 
(Lamaze et al. 1996), other observations suggest the opposite effect in different cell 
types (Lamaze et al. 1997). It has been reported that glucocorticoids can stabilize 
actin filaments by preventing drug-induced disruption or by thickening actin bundles 
in different cells including AtT20 cells (Castellino et al. 1992). Taken together, these 
suggest that glucocorticoids may influence the V1b receptor endocytosis by acting on 
actin filaments.  
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1.3.4 Aims of this study 
Since desensitization of the ACTH response to AVP may have an important 
physiological role in ACTH regulation (Hassan et al. 2003), it is important to 
investigate whether factors that influence ACTH secretion directly may also have 
some impact on this process, as this could contribute significantly to the overall 
regulation of ACTH release.  
 
The overall aim of this project was to investigate the effects of hormonal interaction 
on desensitization of the ACTH response to AVP in ovine anterior pituitary cells. 
Specifically, the first objective of this study was to examine whether CRH at a higher 
concentration than previously tested (but still in the physiological range) affects AVP-
induced ACTH desensitization. The second objective was to investigate the influence 
of cortisol, a major inhibitory factor for ACTH release, on desensitization of the 
ACTH response to AVP. The third part of this study was aimed at investigating the 
effect of combined CRH and cortisol on AVP-induced ACTH desensitization using 
ovine anterior pituitary cells. 
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2 
MATERIALS AND METHODS 
2.1 Materials, Solutions and Media 
For the sources of materials used in this study, refer to Appendix A. 
For the details of all solutions and media used in this study, refer to Appendix B 
2.2 Preparation of Anterior Pituitary Cells 
2.2.1 Collection of sheep pituitaries 
Pituitaries were collected from sexually mature ewes shortly after they were 
slaughtered. Whole heads were collected from either PPCS Ltd. (Belfast, 
Christchurch) or the Malvern Abattoir Ltd. (Malvern, Canterbury) and put on ice for 
transporting back to the School of Biological Sciences, University of Canterbury. The 
heads were then cut posterior-anteriorally with a band saw, and the pituitary gland 
was exposed and dissected out using sterile forceps and scalpel. After removal from 
the head the pituitary glands were placed into chilled, sterile dispersing buffer (DB) 
and transferred to the laboratory.  
2.2.2 Cell dispersion 
Cell preparation was carried out under aseptic condition. Pituitary cells were prepared 
in a laminar flow hood (CF43S, Gelman Sciences, Australia). All instruments and 
glassware used for cell preparation had previously been either autoclaved (15 min, 
121ºC, 15 psi), or heat sterilized in an oven (≥170ºC, 2 h). Similarly, all glassware and 
solutions used were sterile.  
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The pituitary glands were put into a petri dish, and usually 7 intact one were selected. 
The pituitaries were then washed briefly by submerging three times in fresh DB. After 
washing, the pituitaries were put into DB on ice. The connective tissue, the median 
eminence, pituitary stalk and posterior pituitary were removed using scissors and 
forceps. The anterior pituitaries were then placed into a 50 ml centrifuge tube 
containing 20 ml DB that had been put on ice. Following a rinse with 45 ml DB, the 
anterior pituitaries were minced into small pieces (less than 2 mm3) with scissors. 
These pieces were transferred to a trypsinizing flask along with 50 ml of collagenase 
solution (Type Π collagenase; 450 U/ml). The flask was then placed in a 37ºC 
incubator and the tissue suspension was gently stirred on a magnetic stirrer. Usually 
three digestions were done (the first was 20 min long, and the subsequent two were 1 
h each). Cells were collected as described below following each digestion. Firstly, the 
digestion flask was taken out of the incubator, and the supernatant containing the 
dispersed cells was decanted into a 50 ml plastic centrifuge tube. Then the supernatant 
was centrifuged at 200 × g (CR-412, Jouan, France) for 5 min at 4ºC. After 
centrifugation, the cell-free supernatant was returned to the digestion flask for the 
subsequent digestion. The cell pellet was washed once by resuspending the cells in 45 
ml DB using a 10 ml pipette, and then centrifuged as before. The supernatant was 
aspirated, and the cell pellet was resuspended in 10 ml DB, and placed on ice. 
Depending on the size of the pellets obtained from the three digestions, a fourth 
digestion (~30 min), was occasionally done to increase the number of cells. 
  
After all digestions were completed, all of the cells obtained were pooled and washed 
(as above) four times. After the third wash the cells were resuspended and filtered 
through sterile gauze to remove tiny pieces of connective tissue. Following the final 
centrifugation the cells were resuspended in 25 ml of Dulbecco’s modified Eagle’s 
medium (DME; see Appendix B) containing 10% newborn calf serum (DME/NCS), 
and placed on ice. 
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2.2.3 Cell viability determination 
Cell viability was determined by the trypan blue exclusion method. A small volume 
(100-200 µl) of cell suspension was used to do a cell count using a haemocytometer. 
Typically, the viability varied between 75-90 %, and the average was 82.2%. 
2.2.4 Overnight culture  
For perifusion experiments, 20 ml of cell suspension containing 4.5 × 106 viable 
cells/ml DME/NCS was prepared. Aliquots of this suspension (1 ml) were then 
transferred to plastic petri dishes containing 19 ml of DME/NCS. Fifteen of these 
dishes were used for the perifusion experiment (one per perifusion column), and one 
was used for cell viability determination on the day of the perifusion. All dishes were 
then incubated overnight (~18 h) at 37 ºC in a 95% air:5% CO2 incubator. 
2.3 Perifusion Experiments 
2.3.1 The multi-column perifusion system 
Experiments were performed using a multi-column perifusion system, as shown 
diagrammatically in Figure 2.3.1. Cells were put into cell chambers, or columns, and 
solutions were pumped over the cells using a peristaltic pump. Up to 15 columns can 
be perifused simultaneously. Each of the columns has an internal volume of 
approximately 600 µl and can be maintained at a temperature of 37ºC with a water 
jacket during experiments. Using a solenoid switching system the solutions pumped 
over the cells can be rapidly and precisely changed from ‘basal’ solutions (containing 
no hormone) to ‘test’ solutions (containing hormone). This enables the solutions in all 
columns to be changed simultaneously. The effluent from columns was collected via a 
Gilson FC 204 fraction collector (Gilson, France). 
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Y-junction 
Figure 2.3.1 Diagram showing one column from the multi-column perifusion system. Note that there 
are 15 columns arranged in parallel in the actual system 
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2.3.2 Experimental procedure 
On the day of a perifusion experiment, the cells from each plate, that had been 
cultured overnight, were transferred along with the DME/NCS to separate 50 ml 
centrifuge tubes (one plate to one tube) and centrifuged at 275 x g (CR-412, Jouan, 
France) for 5 min at 4ºC. After the supernatant was aspirated, the cells were 
resuspended in 170 µl of a slurry of Sephadex G-25 (fine). The tubes were placed on 
ice prior to loading the cells into the perifusion columns. Before loading the cells, all 
lines were flushed with Krebs Ringer (KR) containing 0.05% alkali-treated casein 
(ATC) and 0.005% L-ascorbate (KR/ATC). The test lines leading to the Y-junctions 
were primed with test solutions. Slurries of Biogel P-2 and Sephadex G-25 (80 µl of 
each) were added sequentially to each of the columns to form a bead bed on which the 
cells would be supported. The bead bed was prevented from draining out by a 10 µm 
mesh Nybolt nylon gauze. The cells, suspended in the slurry of Sephadex, were 
transferred onto this bead bed using a Pasteur pipette. All columns were then filled 
with KR/ATC and sealed with a rubber bung attached to the inflow tube. 
 
Once cell loading had been finished, the pump was switched on to start the 
experiment (0 min). During an experiment, cells were perifused with either a ‘basal’ 
solution (e.g. KR/ATC) or a ‘test’ solution of AVP dissolved in KR/ATC. Changes 
between ‘basal’ and ‘test’ were done using the solenoid switch system. When cells 
were perifused with KR/ATC plus two or more other treatment solutions, a manual 
change was required for transfer between KR/ATC and the second solution. The 
solutions were put into separate tubes (normally 50 ml centrifuge tubes) and placed in 
a 37ºC water bath. These solutions were pumped through the perifusion system tubing 
at a flow rate of ~0.156 ml/min. The effluent from the columns was collected as 5 or 
10 min fractions. These samples were stored at -20ºC, and assayed for ACTH content 
by radioimmunoassay (RIA; usually within one week of sample collection). 
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2.3.3 Design of protocols 
The experimental protocols used in this study were based on a protocol used by 
Hassan et al. (2003) to characterize desensitization of the ACTH response to AVP. 
During the experimental procedure cells were repeatedly stimulated three times at 80 
min intervals with 5-min AVP pulses (100 nM). Desensitization of the ACTH 
response to AVP was induced by pretreating the cells for 15 min with 5 nM AVP 
(excepted where indicated otherwise) immediately preceding the second AVP pulse. 
Cells were perifused with either KR/ATC or KR/ATC containing cortisol for 80 min 
at the beginning of the experiment, which allowed them to recover from loading. 
During this time ACTH secretion fell to a constant, low (basal) level. CRH (0.2 nM) 
was added to the perifusion solution from 80 min onwards, when necessary. AVP 
pulses were given at 120, 200, and 280min. The duration of each experiment was 320 
min.   
  
There were 4-5 different treatments within one experiment. Generally, each treatment 
was assigned to 2-3 columns per experiment and repeated in at least three 
experiments. The details of different concentrations and specific treatment regimes 
used in individual experiments can be found in the following ‘Results’ chapter. 
2.4 ACTH Radioimmunoassay 
2.4.1 Assay reagents 
Solutions 
For the details of all solutions used in the RIAs, see Appendix B 
 
Tracer 
125I-labelled ovine ACTH (125I-oACTH) was used as the tracer for the RIAs in this 
project. Tracer was prepared by Dr. Drusilla Mason using a chloramine T 
radioiodination method, and was carried out in the dedicated facilities of the Endolab, 
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Department of Endocrinology, Christchurch Hospital. In brief, the iodination involved 
incubation of oACTH (a kind gift from Dr C. H. Li; see Appendix A) with 125I for 1 
min in the presence of chloramine T, stopping the iodination reaction with sodium 
metabisulphite, and separating the labelled ACTH from the reaction mixture by high 
performance liquid chromatography.  
 
The tracer was aliquoted into appropriate volumes and stored at -20ºC for up to 
thirteen weeks before use. On the day of use, the tracer was diluted in a 0.05 M 
phosphate buffer containing 0.1% ATC (P/ATC) to give 10,000 cpm/100µl. 
 
ACTH standards 
The standards used in this study were prepared by Dr Drusilla Mason. One ml of an 
ovine ACTH stock solution (500 µg/L) was diluted in P/ATC to give a concentration 
of 10 µg/L. This solution was further diluted in different volumes of P/ATC to give a 
series of ACTH solutions of 10, 5, 3, 2, 1.5, 1, 0.5 and 0.25 µg/L. These standards 
were then aliquoted into 300 or 600 µl aliquots and stored at -20ºC (or -80 ºC for 
long-term storage). P/ATC was used as the zero standard. 
 
ACTH antiserum 
Antiserum (AS) was raised in rabbits by injection with two porcine ACTH 
preparations (ACTH with carboxymethylcellulose and ACTH zinc hydroxide). Two 
batches of AS were used in this study. The initial batch used, Athol Pool 1 (containing 
Athol Bleeds 4, 5, 9, 11, 12, 16; 1975), was provided by Professor Richard Donald 
(Department of Endocrinology, Christchurch Hospital). This was used for assays 1 - 
43 and was diluted 1:1400 in P/ATC. The second batch was Athol Bleed 7 (1975), 
which was provided by Dr Margaret Evans (Department of Endocrinology, 
Christchurch Hospital). This was used in assays 44 - 55 at 1:1000 dilution. All diluted 
AS were stored at -20ºC. 
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 ACTH replicates  
Replicate samples used in this study were prepared by Ali Hassan (12/1997). 
Replicates at three concentrations (high, ~3.0 µg/L; medium, ~1.3 µg/L; low, ~0.4 
µg/L) were included at both the beginning and the end of each assay, and were used to 
indicate the quality of assay. The major steps involved in the preparation of replicates 
were as follows. Surplus cells from a cell preparation were incubated overnight. On 
the following day the cells were exposed to high concentrations of AVP and CRH for 
2 h. After centrifugation, the supernatant was collected and the cell pellet was 
resuspended in KR/ATC, vortexed, and frozen, and thawed to rupture the cells, 
releasing ACTH. The resulting suspension was centrifuged and the supernatant was 
mixed with the supernatant from the first centrifugation. These replicates were stored 
as 1 ml aliquots at -20ºC. 
 
A total of 55 assays were done in this study. The intra-assay coefficients of variation 
were 8.99, 6.12 and 6.17% for the low, medium and high replicates, respectively. The 
inter-assay coefficients of variation were 10.30, 9.68 and 7.85% for low, medium and 
high replicates, respectively. 
2.4.2 Assay set up 
All assays were set up in duplicate in an ice/water bath. From assays 1 to 43, P/ATC 
buffer, ACTH sample (including standards, replicates and experimental samples), 125I-
oACTH tracer and ACTH antiserum (Athol Pool 1) were added sequentially on the 
same day to the appropriate assay tubes (Table 2.1). Non-specific binding tubes were 
included for each set of standards, replicates and samples. The assay tubes were then 
incubated at 4ºC for ~ 24 h prior to separation. 
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Tube Type Buffer Standard 
Sample 
Replicate 
Tracer Antiserum 
NSB (zero std) 150 100 100 0 
Zero std 50 100 100 100 
Other stds 50 100 100 100 
NSB (assay zero) 250 0 100 0 
Zero (assay) 150 0 100 100 
NSB  150 100 100 0 
Replicates 50 100 100 100 
NSB 150 100 100 0 
Set of samples 50 100 100 100 
NSB  150 100 100 0 
Replicates 50 100 100 100 
NSB (assay zero) 250 0 100 0 
Zero (assay) 150 0 100 100 
 
Table 2.1 Protocol for the RIA set up. All volumes are in microlitres. After addition of all reagents the 
tubes were mixed briefly using a rack vortex mixer, and then incubated at 4ºC for 20 - 24 h. 
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From assay 44 to 55, Athol Bleed 7 AS was used to replace Athol Pool 1 AS. The 
assay procedure was similar to the above protocol except that the tracer was added 
after the other three reagents had been incubated together for ~ 24 h at 4ºC (referred to 
as a “pre-incubation”). Following addition of the tracer, the tubes were mixed again 
and a “post-incubation” was carried out for ~ 48 h at 4ºC.  
2.4.3 Assay separation 
The antibody-bound 125I-oACTH was separated from the free labelled hormone by 
fractional precipitation at room temperature. The basic procedure was as follows. At 
the end of the incubation with tracer, 1.2% bovine γ-globulin (50 µl) was added 
immediately to each tube. After the racks were shaken briefly by hand, 18% 
polyethylene glycol solution (1.5 ml/tube) was added. Following vigorous vortex 
mixing the tubes were incubated at room temperature for 15 minutes. The tubes were 
then centrifuged at 4,010 x g, for 15 min at 4ºC (Heraeus Varifuge 3.0R) to precipitate 
the antiserum-bound ACTH. The supernatant was aspirated, and the radioactivity 
(counts/2 min) in each tube was measured using a gamma scintillation counter (1275 
Minigamma counter, LKB Wallac). The data obtained were saved as a computer file 
for later analysis. 
2.5 Data Analysis 
2.5.1 RIA output 
The count file obtained for each RIA was analyzed using the MRIAC RIA program 
(Livesey 1974). This program fits the raw data of the standards into a standard curve. 
This standard curve is then used to calculate the ACTH concentration ([ACTH]) in 
each sample assayed. The value shown in the output is given as the mean of the 
duplicates. A confidence limit of 95% is given for each duplicate. 
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2.5.2 Calculation of ACTH secretion 
ACTH content in each fraction was calculated using the equation: 
                    ACTH content (ng) = [ACTH] in fraction x fraction duration x flow rate 
                                                            (ng/ml)                          (min)                (ml/min) 
The values for the ACTH concentrations of the fractions were obtained from the RIA 
output. Thus, total ACTH secretion during a certain period could be calculated as a 
sum of the ACTH contents in all fractions collected during that period. 
 
In terms of the above, ACTH secretion stimulated by each pre-treatment or test pulse 
was calculated as below: 
                 Stimulated ACTH secretion = Total ACTH secretion – Basal ACTH secretion 
For 100 nM AVP or 100 mM KCl test pulse, total ACTH secretion was calculated for 
a 20 min period from the onset of the pulse; while for the AVP pre-treatment, total 
ACTH secretion was calculated for a 15 min duration (covering the whole pre-
treatment period).  
 
Basal ACTH secretion was calculated using the mean [ACTH] from the three 
fractions immediately before a test pulse or a pre-treatment (when there was a pre-
treatment preceding the second test pulse). It is assumed that these values remain 
constant and equal to the basal secretion during the response. 
2.5.3 Assessment of desensitization 
In this project, the method for assessing the extent of desensitization was adapted 
from Hassan et al. (2003). They showed that, when the ACTH response to the second 
100 nM AVP pulse was compared with the mean of the responses to the first and third 
pulses (Figure 2.5.1a), there was no significant difference between them. Thus, the 
mean of the responses to the first and third pulses was assigned as an intra-column 
control (100%) for the response to the second AVP pulse. The magnitude of 
desensitization was assessed by expressing the response to the second AVP pulse 
following AVP pre-treatment as a percentage of this control. There are two 
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advantages of using this intra-column control. First, it avoids analytical difficulties 
that can arise due to variations in the absolute values of ACTH release between 
individual columns. Second, the control protocol can be omitted once the relationship 
mentioned above has been established, so that there are more columns available to be 
used for other treatments.  
 
In view of this, a series of protocols similar to those used by Hassan et al. (2003) were 
used in present study to test whether the above relationship still held, and to assess the 
impact of additional treatments on this relationship (Figure 2.5.1). In the first three 
experiments in which cells were perifused with KR/ATC before and after three 5 min 
pulses of 100 nM AVP (Figure 2.5.1a), the response to the second AVP pulse was 
significantly less than the mean response to the first and third pulses (88.8±2.1%, n=7, 
P<0.01, t-test). However, this percentage value increased to 100.7±3.2% (n=9, NS, t-
test) in the subsequent experiments. As a result, there were two different control 
values for this treatment. For the first three experiments, 88.8% of the mean response 
to the first and third pulses was taken as a control with the same column. For each 
column that received AVP pre-treatment, the response to the second AVP pulse was 
expressed as a percentage of the mean response to the first and third pulses. This 
percentage value was then normalized by dividing by 88.8% to show the actual 
magnitude of desensitization. In the later experiments, the magnitude of 
desensitization with the same treatment was directly assessed by expressing the 
response to the pre-treated AVP pulse as a percentage of the mean response to the first 
and third pulses. 
 
In the presence of continuous perifusion with CRH or cortisol alone (see Figure 2.5.1 
b & c), the response to the second AVP pulse was not significantly different from the 
mean of the responses to the first and third pulses (99.0±4.1% [n=9, NS, t-test] and 
105.0±2.1% [n=7, NS, t-test], respectively). Thus, with these two treatments, the 
mean of the responses to the first and third AVP pulses was taken as a control to 
assess the extent of desensitization. 
  Materials and Methods 
 29 
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
a
= 5min, 100nM AVP = 100 nM cortisol = 0.2nM CRH
[A
CT
H]
 (µ
g/L
)
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
[A
CT
H]
 (µ
g/L
)
b
 
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
[A
CT
H] 
( µ
g/L
)
c
 
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
d
Time(mins)
[A
CT
H]
 ( µ
g/L
)
 
Figure 2.5.1 ACTH response to AVP with different treatments. Representative data are shown from 
four perifusion columns illustrating the control protocols used in this study. Typically, cells were 
treated with 100 nM AVP for 5 min at 120, 200, and 280 min, with the perifusion medium containing 
(a) no hormone, (b) 0.2 nM CRH (from 80 min), (c) 100 nM cortisol (from 0 min), and (d) CRH and 
cortisol in combination. 
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When both CRH and cortisol were present (see Figure 2.5.1d), the response to the 
second AVP pulse was significantly greater than the mean response to the first and 
third pulses (110.0±2.0%, n=8, P<0.01, t-test). With this treatment, for each column 
that received AVP pre-treatment, the response to the second AVP pulse was expressed 
as a percentage of the mean response to the first and third pulses. This percentage 
value was then normalized by dividing by 110% to show the extent of desensitization 
in the presence of CRH and cortisol in combination.   
2.5.4 Statistics 
Microsoft Excel and GraphPad Prism 4 were used for data analysis. Data were 
statistically analyzed using Student t-test and one-way or two-way ANOVA. Details 
of the analyses are indicated in the text. P<0.05 was considered as significant. All 
data were reported as mean ± SEM. 
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RESULTS 
3.1 Effect of CRH on Desensitization of the ACTH Response to AVP 
Both CRH and AVP are important stimulators for ACTH release. In many species 
such as rats, sheep and horses, they can act alone, or act together to give synergistic 
effects (Gillies et al.1982; Evans et al. 1988; Liu et al. 1990; Evans et al. 1993). In 
addition to stimulate ACTH secretion, prolonged or repeated exposure of  the pituitary 
gland to CRH or AVP results in attenuated ACTH responsiveness, or desensitization. 
Recently Hassan et al. (2003) have characterised desensitization of the ACTH 
response to AVP and CRH in perifused ovine anterior pituitary cells, and suggested 
that desensitization may play an important role in regulating ACTH secretion in vivo. 
In view of the suggestion that CRH may act in a permissive role, setting the overall 
responsiveness of corticotrope cells, while AVP is the main dynamic ACTH-releasing 
factor (Antoni 1993; Evans et al. 1996), Hassan and coworkers (2003) also 
investigated whether a constant perifuson with CRH could overcome or enhance 
AVP-induced ACTH desensitization. Data demonstrated from their studies show that 
a low level, constant CRH ‘background’ (0.01 nM) did not have any significant effect 
on AVP desensitization. However, pituitary portal CRH concentrations can increase 
dramatically to levels more than an order of magnitude greater than this under certain 
conditions in conscious sheep. For example, maximal CRH concentrations of ~0.2 nM 
have been reported for acute haemorrhage (reviewed in Mason et al. 2002) and ~0.4 
nM for insulin-induced hypoglycaemia (Caraty et al. 1990). It was therefore important 
to investigate whether a CRH concentration in this range (0.2 nM) modifies 
desensitization of the ACTH response to AVP.  
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 3.1.1 Development and validation of CRH protocols 
In earlier experiments investigating the effect of 0.01 nM CRH on AVP 
desensitization, CRH was included in the perifusion medium at a constant 
concentration from 80 min onwards (Hassan et al. 2003). This treatment was used in 
conjunction with the protocol described in Section 2.3.3, in which AVP (100 nM) was 
given as three 5 min pulses at 120, 200 and 280 min, and desensitization was induced 
by pretreating cells for 15 min with 5 nM AVP immediately before the second AVP 
pulse. At a concentration of 0.01 nM, CRH on its own did not stimulate ACTH 
secretion. Therefore basal ACTH secretion in CRH-treated cells was comparable to 
control cells perifused with KR/ATC alone.  
 
In the present study, a CRH concentration of 0.2 nM was used. From earlier work in 
the laboratory (Hassan et al. 2003) it was clear that this concentration would stimulate 
ACTH secretion with a peak at ~10-15 min after the onset of CRH stimulation, and 
that secretion was then likely to drop over the next 5-10 min to a slowly declining 
“plateau”, or fall gradually from the peak. It is necessary to have a relatively constant 
ACTH secretion immediately prior to each AVP pulse in order to calculate AVP-
stimulated ACTH secretion (see Section 2.5.2). Therefore, the timing of the onset of 
CRH perifusion relative to the first AVP pulse needed to be assessed in initial 
experiments looking at the effect of CRH on AVP desensitization.      
 
In the first experiment, cells were exposed to CRH from 90 min (i.e. 30 min before 
the first 100 nM AVP pulse). It was observed that for some columns perifused with 
CRH, the initial ACTH response to CRH had not reached a “plateau” before the first 
AVP pulse was given (Figure 3.1.1a). Thus, in subsequent experiments, cells were 
perifused with CRH from 80 min, as shown in Figure 3.1.1b. As a result, the baseline 
immediately before the first AVP pulse was relatively steady.  
 
  Results 
 33 
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
a
 5 min, 100 nM AVP  0.2 nM CRH
[A
CT
H]
 (µ
g/L
)
 
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
b
[A
CT
H]
 ( µ
g/L
)
 
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
c
Time(mins)
[A
CT
H]
 ( µ
g/L
)
 
Figure 3.1.1 ACTH secretion in response to continuous CRH exposure. Data from three individual 
columns illustrating the initial experimental protocols are shown. Cells were treated with 5-min pulses 
of 100 nM AVP after 120, 200, and 280 min of perifusion, with a 0.2 nM CRH ‘background’ from (a) 
90 min and (b) 80 min. In (c), cells were treated with 0.2 nM CRH alone from 80 min, resulting in 
variations in basal ACTH secretion. 
  Results 
 34 
To assess the impact of prolonged CRH exposure on basal ACTH secretion 
throughout the experiment, CRH alone was perifused from 80 min onwards (Figure 
3.1.1c). It can be seen that after the high secretion during the initial 30-40 min, the 
ACTH release in response to CRH fell very slowly during the remainder of the 
perifusion. Despite this, the basal secretion immediately before 120, 200 and 280 min 
was not dramatically different from the basal secretion immediately after the same 
time point. Since these three time points are corresponding to the onset of each AVP 
pulse in Figure 3.1.1b, this indicates that variations in basal secretion in the presence 
of CRH should have minimal effect on the calculation of ACTH release from each 
AVP pulse. 
3.1.2 Desensitization of the ACTH response to AVP in the presence of CRH 
In the absence of CRH, 15 min AVP (5 nM) pre-treatment significantly reduced the 
response to the second AVP pulse (to 77.6±3.3% of control, n=10, P<0.001, t-test) as 
shown in Figure 3.1.2. A significantly greater reduction (P<0.001, t-test) was seen in 
the presence of CRH (0.2 nM): to 48.1±4.3% (n=12, P<0.0001, t-test) of control, i.e. 
the mean of the responses to the first and third pulses. Data are summarized in Figure 
3.1.3.  
 
More ACTH was released in response to 100 nM AVP when cells were continuously 
exposed to CRH, than in its absence (see Figure 3.1.2). This raises the question as to 
whether the greater reduction in response to the second AVP pulse seen in the 
presence of CRH is due to a true desensitization or to depletion of ACTH. This was 
assessed by replacing the second AVP pulse with a 5-minute KCl pulse (100 mM), 
with or without AVP pre-treatment in the presence of continuous CRH perifusion 
(Figure 3.1.4). The mean of the responses to the first and third pulses was taken as a 
control. Both the responses to a KCl pulse and the second AVP pulse were expressed 
as a percentage of this control for the same column.  
 
  Results 
 35 
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
a
 5 min, 100 nM AVP 15 min, 5 nM AVP  0.2 nM CRH
[A
CT
H]
 (µ
g/L
)
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
b
[A
CT
H]
 (µ
g/L
)
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
[A
CT
H]
 (µ
g/L
)
c
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
0
1
2
3
4
5
6
Time(mins)
[A
CT
H]
(µ
g/L
)
d
 
Figure 3.1.2 Desensitization of the ACTH response to AVP in the presence of CRH. Data from four 
individual columns illustrating the experimental protocols are shown. Cells were treated with 5-min 
pulses of 100 nM AVP after 120, 200, and 280 min of perifusion in all columns. To induce 
desensitization the second AVP pulse was preceded by a pre-treatment with 5 nM AVP for 15 min in 
either (b) the absence or (d) presence of 0.2 nM CRH (from 80 min). 
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Figure 3.1.3 Effect of CRH on desensitization of the ACTH response to AVP. Data show the ACTH 
response to the second AVP pulse in either the absence or presence of a pre-treatment with 5 nM AVP 
for 15 min, with (+CRH) or without (-CRH) a 0.2 nM CRH ‘background’. Asterisks indicate a 
statistically significant difference between the ‘No pre-treatment’ and ‘AVP pre-treatment’ groups, and 
between the two ‘AVP pre-treatment’ groups. Data are mean ± SEM (*** P<0.001, t-test, n=7-12 for 
each group).  
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 Figure 3.1.4 ACTH response to a KCl pulse in the presence of CRH. Representative data are shown 
from two perifusion columns illustrating the protocol used in these experiments. In the presence of 0.2 
nM CRH, cells were treated with a 100 mM KCl pulse (starting at 200 min) for 5 min in (a) the absence 
or (b) presence of 5 nM AVP pre-treatment.  
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Data from two experiments showed that, the response to a KCl pulse following AVP 
pre-treatment (39.1±2.0% of control, n=10) was significantly less than the response to 
the KCl pulse that were not pre-treated (63.3±6.1% of control, n=10, P<0.01, t-test). 
Since KCl stimulates ACTH release by directly depolarizing the cell membrane rather 
than by activating a cell surface receptor, desensitization of the ACTH response to 
AVP should not reduce the ACTH response to a KCl pulse. In view of this, the 
reduction in response to a pre-treated KCl pulse could be due to depletion of cellular 
ACTH.  
 
The response to the second AVP pulse in the presence of CRH was reduced from 
100% of control, in the absence of AVP pre-treatment , to 37.1±1.7% following pre-
treatment  (n=9, P<0.0001, t-test). This reduction (62.9%) is greater than that seen 
with AVP pre-treatment of the KCl pulse (from 63.3±6.1% to 39.1±2.0%, i.e. 24.2%). 
This suggests that the reduction in response to AVP following AVP-pre-treatment in 
the presence of CRH involves both a specific desensitization process and ACTH 
depletion. Taken together, these results indicate that depletion of cellular ACTH 
contributes, at least partially, to the greater reduction in response to the second AVP 
pulse following pre-treatment in the presence of CRH. Results are summarized in 
Figure 3.1.5. 
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Figure 3.1.5 Effect of AVP pre-treatment on the ACTH responses to KCl and AVP pulses in the 
presence of CRH. Data show the response to a KCl pulse or the second AVP pulse in either the absence 
(open bar) or the presence (black bar) of a pre-treatment with 5 nM AVP for 15 min, with a 0.2 nM 
CRH ‘background’. Asterisks indicate a statistically significant difference between the ‘No pre-
treatment’ and ‘AVP pre-treatment’ groups. Data are mean ± SEM (** P<0.01, *** P<0.001, t-test, 
n=9-10 for each group). 
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In view of the ACTH depletion seen with the protocol discussed above, the effect of 
CRH on AVP desensitization could not be accurately determined from this data. Thus, 
a slightly modified experimental protocol was tested. The concentration of AVP used 
for the pre-treatment was reduced from 5 to 0.5 nM, while the rest of the protocol 
remained the same (Figure 3.1.6). In a previous study, 0.5 nM AVP pre-treatment did 
not have a significant effect on the response to a subsequent AVP pulse (Hassan et al. 
2003). Results obtained in the current study were consistent with this: In the absence 
of CRH, following 0.5 nM AVP pre-treatment, the response to the second pulse was 
99.1±3.7% of control (Figure 3.1.6a, n=4, NS, t-test). In contrast to this, in the 
presence of CRH, pre-treatment  with 0.5 nM AVP substantially reduced the response 
to the second pulse to 66.7±2.2 % of control (Figure 3.1.7, n=6, P<0.0001, t-test). 
 
Again, a KCl pulse protocol was used to determine whether the reduction in response 
seen following 0.5 nM AVP pre-treatment in the presence of CRH was due to AVP-
specific desensitization or to depletion of ACTH (Figure 3.1.8). In the presence of 
CRH, AVP pre-treatment did not reduce the response to a KCl pulse compared with 
the response of the cells that were not pre-treated (73.0±4.5% c.f. 65.6±3.0%, 
respectively, of control, i.e. mean of the responses to the first and third AVP pulses; 
n=3, NS, t-test). In contrast, 0.5 nM AVP pre-treatment in the presence of CRH 
reduced the response to the second AVP pulse from 100% to 63.6±1.1% of control 
(n=3, P<0.001, t-test). Since 0.5 nM AVP pre-treatment had no effect on the ACTH 
response to the subsequent KCl pulse, it was obvious that the reduction in response to 
the second AVP pulse induced by the same pre-treatment was due to an AVP-specific 
desensitization process rather than depletion of cellular ACTH. 
 
In summary, these data indicate that CRH (0.2 nM) can interact with AVP (0.5 nM) to 
augment AVP-induced desensitization of the ACTH response.  
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Figure 3.1.6 Desensitization of the ACTH response to AVP in the presence of CRH. Representative 
data are shown from two perifusion columns illustrating the protocols used in these experiments. 
Desensitization was induced using a pre-treatment with 0.5 nM AVP prior to the second AVP pulse in 
either (a) the absence or (b) presence of 0.2 nM CRH ‘background’. 
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Figure 3.1.7 Effect of CRH on desensitization of the ACTH response to AVP. Data show the ACTH 
responses to the second AVP pulse following a 15 min pre-treatment with 0.5 nM AVP, in either the 
absence (-CRH) or the presence (+CRH) of a 0.2 nM CRH ‘background’. Data are reported as mean ± 
SEM (*** P<0.001, t-test).  
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 Figure 3.1.8 ACTH responses to KCl in the presence of CRH. Representative data are shown for two 
perifusion columns illustrating the protocols used in these experiments. In the presence of 0.2 nM 
CRH, cells were treated with a 5 min KCl pulse in (a) the absence or (b) presence of 0.5 nM AVP pre-
treatment.  
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3.2 Effect of Cortisol on Desensitization of the ACTH Response to 
AVP 
The pituitary gland has been considered as an important site of steroid feedback. In 
many species such as rat (Abou-Samra et al. 1986; Bilezikjian & Vale 1987), horse 
(Evans et al. 1993b) and sheep (Clark et al. 1994), continuous exposure to 
glucocorticoids (2-4 h) significantly inhibited CRH- or AVP-stimulated ACTH 
secretion from cultured anterior pituitary cells. However, this inhibitory effect appears 
more efficient on the ACTH response to CRH than that to AVP (Bilezikjian & Vale 
1987; Evans et al. 1993b), indicating that AVP-stimulated ACTH release is somewhat 
resistant to steroid feedback. As a support of this, DEX pretreatment of perifused rat 
anterior pituitary cells for 2 h significantly reduced the ACTH response to CRH and 
the sustained plateau phase of the response to AVP, but had no effect on the spike 
phase of the response to AVP, which is mediated by AVP-stimulated IP3 formation 
(Oki et al. 1991). Long-term DEX treatment even resulted in significant increase in 
AVP-induced IP3 production, but is accompanied with a reduction in V1b receptor 
(Rabadan-Diehl & Aguilera 1998). These indicate that a complex interaction between 
AVP and glucocorticoids is involved in regulating ACTH secretion in response to 
AVP, and this may also affect AVP-induced ACTH desensitization. Therefore, the 
following experiments were designed to investigate the effect of cortisol, a major 
glucocorticoid in sheep, on desensitization of the ACTH response to AVP stimulation 
in sheep anterior pituitary cells. 
 
The inhibitory effect of glucocorticoids on ACTH secretion falls into three 
timeframes, namely fast (within minutes), intermediate (2-10 h) and slow (hours to 
days) steroid feedback, which are mediated by different mechanisms (Keller-Wood & 
Dallman 1984). In view of this, in the present study, continuous cortisol perifusion 
starts at 0 min, which is 2 h before the first AVP pulse is given, so that the action of 
cortisol in the responses to the three AVP pulses involves similar mechanisms to the 
intermediate feedback.  
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 The experimental protocols used were similar to those in Section 3.1, except that 
cells were perifused with cortisol rather than CRH. Cells were stimulated with three 
5-min AVP (100 nM) pulses and desensitization was induced by a 15 min pre-
treatment with 5 nM AVP. In sheep, the total plasma cortisol concentration under 
basal conditions  is ~50 nM, with ~65% bound to cortisol-binding globulin, ~20% 
bound to albumin, and ~15% (i.e. ~8 nM) free (derived from Figures 1 & 4, Gayrard 
et al. 1996). Some stressful stimuli, such as transport and scrapie, can increase plasma 
cortisol levels up to 60 ng/ml (~180 nM; Schelcher et al. 1999; Smith & Dobson 
2002). Therefore, concentrations of cortisol used in this study ranged from 10-500 
nM. 
3.2.1 Effect of continuous perifusion with cortisol on AVP-stimulated ACTH 
release 
Consistent with previous reports (Abou-Samra et al. 1986; Evans et al. 1993b; Clark 
et al. 1994), cortisol exhibited an overall inhibitory effect on AVP-stimulated ACTH 
release (Figure 3.2.1). For example, in the presence of 100 nM cortisol, the ACTH 
response to the first AVP pulse was reduced to ~40% of controls that were not 
exposed to cortisol (Figure 3.2.1a). It was also noted that in the presence of cortisol 
the responses to the three AVP pulses were very similar (see Figure 3.2.1b). This 
contrasts with the progressive decrease in magnitude of the three ACTH peaks seen in 
the absence of cortisol in this study (see Figure 3.2.1a).  
 
Because cortisol was prepared as a 1 mM stock in 95% ethanol (see Appendix B), and 
subsequently diluted into KR/ATC to give the final cortisol concentrations used for 
perifusion, possible effects of the vehicle on the ACTH response to AVP were tested. 
Cells were stimulated with three AVP pulses in both the absence and presence of 
continuous ethanol perifusion from 0 min. AVP-stimulated ACTH release was not 
affected by ethanol at the maximum concentration used in the cortisol experiments 
(0.0475%, NS, Two-way ANOVA with Bonferroni’s test, n=3).  
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Figure 3.2.1 Continuous cortisol on the ACTH response to AVP. Data from two individual columns 
illustrating the experimental protocols are shown. Cells were treated with 5-min pulses of 100 nM AVP 
after 120, 200, and 280 min of perifusion in either (a) the absence or (b) presence of 100 nM cortisol 
from 0 min. 
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3.2.2 AVP desensitization in the presence of cortisol 
Following a 15 min AVP (5 nM) pre-treatment in the absence of cortisol, the response 
to the second pulse was reduced to 66.7±1.9% of control (Figure 3.2.2a, n=10). In the 
presence of 100 nM cortisol, a significantly smaller reduction in the response to the 
second pulse was seen following the same pre-treatment (to 78.4±1.7% of control, 
n=10, P<0.001, t-test, Figure 3.2.2c).  
3.2.3 Effect of cortisol concentration on AVP desensitization 
The inhibitory effect of cortisol on AVP-stimulated ACTH secretion is dose-
dependent (Evans et al., 1993). To investigate whether the inhibitory effect of cortisol 
on desensitization of the ACTH response to AVP is also dose dependent, three 
concentrations of the steroid were tested. In the presence of 10, 100 and 500 nM 
cortisol, the response to the second AVP pulse following pre-treatment was 
79.5±4.4% (n=6), 78.4±1.7% (n=10), and 84.0±4.8% (n=5) of control, respectively. 
The magnitude of AVP desensitization was significantly decreased with all three 
cortisol concentrations compared with that seen in the absence of cortisol (66.7±1.9% 
of control, P<0.01, One way ANOVA with Tukey’s test, n=5-10). However, the 
magnitude of the effect of cortisol on AVP desensitization did not vary with the 
cortisol concentration used (NS, One-way ANOVA with Tukey’s test, n=5-10). 
Representative results from four columns are shown in Figure 3.2.2. Combined data 
are summarized in Figure 3.2.3.  
 
Overall, these data suggest that cortisol reduces the magnitude of desensitization of 
the ACTH response to AVP. However, over the range of cortisol concentrations 
investigated in this project, there is no evidence that this effect is dose-dependent. 
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Figure 3.2.2 Different concentrations of cortisol on desensitization of the ACTH response to AVP. 
Representative data from four independent perifusion columns are shown. The second AVP pulse was 
pre-treated with 5 nM AVP for 15 min in (a) the absence, or the presence of (b) 10 nM, (c) 100 nM, 
and (d) 500 nM cortisol from 0 min. 
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Figure 3.2.3 Effect of concentration of cortisol on desensitization of the ACTH response to AVP. Data 
show the ACTH response to the second AVP pulse in either the absence (0 nM) or the presence of a 10, 
100 or 500 nM cortisol ‘background’ when the pulse was immediately preceded by a 15 min pre-
treatment with 5 nM AVP. Asterisks indicate a statistically significant difference between that 
treatment and the control (open bar). Effect of cortisol between 10, 100 and 500 nM were not 
significantly different from each other (NS). Data are mean ± SEM (* P<0.05, ** P<0.01, One-way 
ANOVA with Tukey’s test, n=5-10).  
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3.3 Effect of CRH and Cortisol in Combination on AVP 
Desensitization 
ACTH secretion is influenced not only by individual actions of AVP, CRH or 
glucocorticoid, but also by a complex interaction between these hormones (Evans et 
al. 1996). Several studies have suggested that the inhibitory effect of glucocorticoids 
on ACTH secretion at the pituitary gland in response to CRH or AVP can be 
overcome by CRH application together, or by the combined action of CRH and AVP 
(Abou-Samra et al. 1986; Shipston & Antoni 1991; 1992a; McFarlane et al. 1995; 
Evans et al. 1996). For example, in perifused horse anterior pituitary cells, continuous 
presence of CRH (0.02 nM from 0 min) protected the ACTH response to 5-min pulses 
at 30 min intervals with 10 nM AVP (from 30 min) from cortisol (starts at -100 min) 
inhibition (Evans et al., 1996). In rat anterior pituitary cells, the magnitude of 
corticosterone inhibition of CRH-induced ACTH response could be reduced by 
simultaneous CRH application (Shipston & Antoni, 1992a) or the presence of CRH 
and AVP together (Lim et al. 2002). Results obtained in adrenalectomized sheep 
show that an intravenous cortisol replacement equivalent to the upper limit of the 
normal unstressed range was sufficient to abolish the ACTH response to exogenous 
CRH and AVP alone, but not to CRH and AVP in combination (McFarlane et al. 
1995). Taken together, these results clearly suggest that a complex interaction 
between CRH, AVP and glucocorticoids plays an important role in regulating ACTH 
secretion from the anterior pituitary. Based on this, and the results presented in 
Section 3.1 & 3.2, experiments were aimed at investigating the effects of CRH and 
cortisol in combination on AVP desensitization.  
3.3.1 Effect of CRH plus cortisol on AVP-induced ACTH secretion  
CRH (0.2 nM) and cortisol (100 nM) were perifused continuously in combination 
from 80 min and 0 min, respectively. Cells were treated with three 5-min AVP pulses 
(100 nM) at 120, 200 and 280 min in both the absence and presence of CRH and 
cortisol in combination. A 15 min pre-treatment with 5 nM AVP was given prior to 
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the second pulse. The response to the first AVP pulse was not significantly different 
in either the absence or the presence of CRH and cortisol in combination (Figure 
3.3.1, NS, t-test, n=3). Furthermore, in the presence of both hormones, the response to 
the second pulse was the largest of the responses to the three AVP pulses (see Figure 
3.3.1c). This differs from the profile seen in the absence of CRH and cortisol, where 
the responses to the three AVP pulses decreased gradually and progressively (see 
Figure 3.3.1a).  
3.3.2 AVP desensitization in the presence of CRH and cortisol in combination 
Results combined from three experiments showed that, following 15 min AVP (5 nM) 
pre-treatment, in the absence of CRH and cortisol, the response to the second pulse 
was 66.2±1.7% of control (Figure 3.3.1b, n=7). When both CRH and cortisol were 
present (see Figure 3.3.1d), AVP pre-treatment caused a significantly greater 
reduction in the response to the second AVP pulse (to 46.5±1.7% of control, n=8, 
P<0.0001, t-test). These results are summarized in Figure 3.3.2. 
 
To determine whether the greater reduction in response to the second pulse seen after 
AVP pre-treatment  in the presence of cortisol plus CRH was caused by depletion of 
ACTH stores or a specific desensitization, a KCl experiment similar to those 
described previously was performed (Figure 3.3.4). After being expressed as a 
percentage of the mean of the responses to the first and third pulses, the response to a 
KCl pulse without pre-treatment was not significantly different from the response 
following pre-treatment (90.9±3.8% e.f. 98.3±4.3%, respectively, n=3, NS, t-test). 
These results differ greatly from those described in section 3.3.2 and clearly show that 
the greater reduction seen in response to the second AVP pulse in the presence of both 
CRH and cortisol was not due to ACTH depletion. 
 
In summary, desensitization of the ACTH response to AVP was significantly 
enhanced in the presence of CRH (0.2 nM) and cortisol (100 nM) in combination. 
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 Figure 3.3.1 Desensitization of the ACTH response to AVP in the presence of CRH & cortisol. Data 
from four individual columns illustrating the experimental protocols are shown. Cells were treated with 
5-min pulses of 100 nM AVP after 120, 200 and 280 min of perifusion in all columns. To induce 
desensitization the second AVP pulse was preceded by a pre-treatment with 5 nM AVP for 15 min in 
either (b) the absence or (d) presence of 0.2 nM CRH (from 80 min) and 100 nM cortisol (from 0 min) 
in combination. 
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Figure 3.3.2 Effect of CRH and cortisol in combination on desensitization of the ACTH response to 
AVP. Data show the ACTH response to the second AVP pulse in either the absence (open bar) or 
presence (black bar) of a pre-treatment with 5 nM AVP for 15 min, with (+CRH & cortisol) or without 
(-CRH & cortisol) 0.2 nM CRH and 100 nM cortisol in combination. Asterisks indicate a statistically 
significant difference between the ‘No pre-treatment’ and the ‘AVP pre-treatment’ groups, and 
between the two ‘AVP pre-treatment’ groups. Data are mean ± SEM (*** P<0.001, t-test, n=7-9 for 
each group).  
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Figure 3.3.3 ACTH responses to KCl in the presence of CRH & cortisol. Representative data are 
shown for two perifusion columns illustrating the protocol used in these experiments. In the presence of 
0.2 nM CRH and 100 nM cortisol, cells were treated with a 5 min KCl pulse (starting at 200 min) in the 
(a) absence or (b) presence of 5 nM AVP pre-treatment.  
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4 
DISCUSSION 
4.1 Influence of CRH on Desensitization of the ACTH response to 
AVP 
This study showed that in the presence of continuous CRH (0.2 nM from 80 min 
onwards), AVP pretreatment (0.5 nM) induced significant desensitization of the 
ACTH response to subsequent 100 nM AVP pulse, whereas no desensitization was 
observed in the absence of CRH. This demonstrated that CRH (0.2 nM) promoted 
AVP-induced ACTH desensitization in perifused ovine anterior pituitary cells. This is 
consistent with the findings of Evans et al. (1988). These researchers observed that 
repetitive AVP or CRH pulses resulted in gradual loss of ACTH responsiveness 
(defined as desensitization of the ACTH response) in perifused sheep anterior 
pituitary cells. This decrease in responsiveness was greater when CRH and AVP were 
given together as pulses than when either was given alone (Evans et al. 1988), 
indicating that CRH can augment AVP-induced ACTH desensitization. Later studies 
in perifused horse anterior pituitary cells showed that the decrease in responsiveness 
to repeated AVP pulses was influenced in a concentration-dependent manner by 
continuous perifusion of CRH (1-25 pM): the higher the CRH concentration, the 
greater the decrease in ACTH responsiveness (Evans et al. 1993a).  The results 
presented in this thesis with 0.2 nM CRH and those reported previously from our 
laboratory (Hassan et al. 2003) showing a lack of effect on AVP-induced 
desensitization of a low level of CRH (0.01 nM)  are qualitatively similar, but 
quantitatively different, to those of Evans et al. (1993a). It is likely that in perifused 
sheep anterior pituitary cells, the effect of CRH on desensitization of the ACTH 
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response to AVP is concentration-dependent, but that it has a higher threshold which 
falls between 0.01 – 0.2 nM.  
 
General mechanisms involved in GPCR desensitization include receptor uncoupling 
due to phosphorylation, receptor internalization and receptor down-regulation, as 
described in Section 1.3.1. Data indicate that rapid AVP-induced desensitization of 
the ACTH response in sheep anterior pituitary cells may involve both phosphorylation 
and internalization of V1b receptor (Hassan & Mason 2005). Therefore, it is possible 
that CRH influences the magnitude of AVP desensitization by modifying V1b 
receptor phosphorylation and/or internalization. There is evidence that CRH enhances 
V1b receptor endocytosis. Incubation of rat anterior pituitary cells with CRH (~21 
nM; converted data) for 30 min significantly increased the rate of V1b receptor 
internalization (Mogenson et al. 1988). It is not known whether the CRH 
concentration used in the current study (0.2 nM) is sufficient to influence V1b 
receptor internalization. 
 
CRH may affect the AVP desensitization process by directly or indirectly modulating 
V1b receptor phosphorylation. The protein kinase(s) responsible for anterior pituitary 
V1b receptor phosphorylation has not been identified to date, but it has been shown 
that neither PKC nor casein kinase 1α is involved in this process (Hassan & Mason 
2005). Since the V1b receptor contains a C-terminus GRK consensus motif (Berrada 
et al. 2000), it is likely that a specific GRK(s) is involved in V1b receptor 
phosphorylation. If this were the case, the effect of CRH on AVP-induced ACTH 
desensitization may be achieved by enhancing GRK activity. For example, PKA can 
increase the activity of GRK2 by phosphorylation, and thus enhancing GRK2-
mediated desensitization of β2AR (Kohout & Lefkowitz 2003).  Since CRH leads to 
activation of PKA in pituitary cells, this could provide a mechanism for enhancement 
of AVP-induced ACTH desensitization. CSPs, such as recoverin and CaM, are able to 
alter the activities of GRKs in different GPCRs, however since they exhibit inhibitory 
effects on GRK activity in all cases investigated (Pronin et al. 1997; Sallese et al. 
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2000) it is unlikely that CSP regulation of GRKs contributes to enhancement of AVP-
induced ACTH desensitization by CRH.  
 
It was also noted that the ACTH response to AVP pulses was potentiated by the 
presence of continuous CRH, with the effect on the response to the first pulse being 
most evident. This is not surprising as the synergistic effect on ACTH secretion 
between CRH and AVP is well established. The possible mechanisms include AVP 
stimulating CRH-induced cAMP generation (Abou-Samra et al. 1987), CRH 
promoting AVP-stimulated IP3 production (Grammatopoulos et al. 2001), and 
interactions between Ca2+ and activation of PKA (Won & Orth 1995; Lim et al. 
1998).  As described in Section 1.2.1, depletion of IP3-sensitive Ca2+ stores 
suppressed the ACTH response to CRH, suggesting a crucial role for this Ca2+ store in 
the ACTH response to PKA-dependent pathway (Won & Orth 1995). In addition, 
increased intracellular free Ca2+ potentiates the ACTH response to cAMP in mouse 
AtT-20 cells (Lim et al. 1998). It appears that a complex interaction between CRH, 
AVP, and Ca2+ mobilization contributes to the regulation of the ACTH release in 
response to CRH and AVP together.  
 
The gradual loss of synergism with CRH apparent in the responses to the second and 
third AVP pulses may be due to CRH-R1 desensitization, resulting in loss of CRH 
activation with time. It has been reported that preincubation of rat anterior pituitary 
segments with CRH for 4 h significantly reduced the CRH-R1 activity, abolishing the 
ACTH response to subsequent CRH challenge (Holmes et al. 1984) 
 
In the present study, an initial pretreatment with 5 nM AVP caused a large decrease in 
response to a subsequent AVP pulse in the presence of CRH (0.2 nM). However, the 
same pretreatment also reduced the ACTH response to a subsequent KCl (100 mM) 
pulse.  This indicated the involvement of other factors, such as depletion of cellular 
ACTH. Newly synthesized ACTH might not be enough to compensate for the 
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substantial ACTH release in response to CRH and AVP in combination, resulting in 
reduced ACTH stores.  
 
In previous study, the IC50 value for desensitization of the ACTH response to AVP 
(6.5 nM; Hassan et al. 2003) is comparable to hypophyseal portal AVP (up to 6 nM in 
the sheep; reviewed in Mason et al. 2002). This has been interpreted as an indication 
that the physiological role of rapid AVP desensitization seen in vitro is to limit the 
maximum ACTH response to AVP rather than to prevent ACTH secretion (Hassan et 
al. 2003). Since it has been suggested that CRH acts in a permissive role to set the 
overall responsiveness of the corticotrope to fluctuations in AVP secretion (Antoni 
1993; Evans et al. 1996), it is possible that, the major role of a lower level of CRH 
(0.01 nM), which was used previously, is to potentiate the ACTH response to AVP. 
When CRH increases during stressful conditions, to a level similar to that used in the 
present study (0.2 nM), CRH may function not only as a synergistic factor in the 
response to AVP, but may also help to limit the maximum response by enhancing the 
magnitude of AVP-induced desensitization of the ACTH response. Furthermore, in 
the presence of CRH, pre-treatment with an AVP concentration as low as 0.5 nM 
induced significant desensitization to a subsequent AVP pulse. This provides further 
support for the suggestion that AVP desensitization occurs under physiological 
conditions.  
 
Overall, the present study demonstrates that CRH significantly enhances 
desensitization of the ACTH response to AVP in ovine anterior pituitary cells. The 
concentrations of CRH and AVP used in this study suggest that this influence may be 
important under physiological conditions, especially in response to stressful stimuli. 
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4.2 Influence of Cortisol on Desensitization of the ACTH Response to 
AVP 
Consistent with previous findings (Abou-Samra et al. 1986; Evans et al. 1993b; Clark 
et al. 1994), continuous perifusion with cortisol showed an overall inhibitory effect on 
the ACTH response to AVP pulses in the present study. In addition to this general 
effect, this study demonstrated that cortisol application also influences AVP-induced 
desensitization of the ACTH response.  In contrast to CRH, continuous cortisol 
perifusion significantly reduced the magnitude of AVP desensitization in ovine 
anterior pituitary cells. The reduction in response to the second AVP pulse following 
AVP pretreatment was significantly smaller in the presence of cortisol than that in its 
absence. These results conflict with previous observations, which showed the 
presence of continuous cortisol (100 nM) did not affect the reduction in response to 
repeated AVP pulses in perifused horse pituitary cells (Evans et al. 1996). Since the 
physiological levels of cortisol in the horse (111-322 nM; Alexander et al. 1993) are 
much higher than those in the sheep (~50 nM; Gayrard et al. 1996), the sensitivity of 
horse and sheep anterior pituitary cells to cortisol may be different. However, in the 
present study, cortisol at 10, 100 and 500 nM reduced the magnitude of AVP 
desensitization to a similar extent, providing no evidence that this effect of cortisol is 
dose-dependent. Other factors, such as species, steroid application regimes and 
experimental design (Antoni 1993) may influence the effect of cortisol. It has been 
shown that proteins in the medium can affect the action of cortisol (Kemppainen et al. 
1991).  
 
Since cortisol and CRH elicit opposite effect on desensitization of the ACTH response 
to AVP, it is likely that cortisol influence V1b receptor phosphorylation and 
internalization in a way that is contrary to that of CRH, such as inhibiting receptor 
phosphorylation or slowing down the rate of internalization.  As described by Keller-
Wood & Dallman (1984), intermediate steroid feedback (2-10 h application) induces 
new protein synthesis. Since AVP pretreatment was given at 185 min from the onset 
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of cortisol perifusion in this study, it is likely that some cortisol-induced proteins were 
involved in the regulation of cortisol effect on AVP desensitization. It has been shown 
that both CaM mRNA (10-fold) and protein level (2-fold) are enhanced after 90 min 
DEX administration in mouse AtT20 cells (Shipston & Antoni 1992b; Shipston 
1995). Since CaM is implicated to inhibit the activities of multiple GRKs including 
GRK2 to GRK6 in different GPCRs (Pronin et al. 1997; Sallese et al. 2000), 
enhancement of CaM levels by glucocorticoids promotes the inhibitory effect on 
GRKs, thereby preventing GRK-mediated GPCR desensitization.  
 
Actin polymerization is indicated to play a role in clathrin-mediated endocytosis 
(Kaksonen et al. 2006). However, there are conflicting results about the effect of 
actins on receptor-mediated endocytosis. For example, Lamaze and coworkers (1996) 
have shown that stimulation of actin filament assembly at the cortex by GTPase 
activation inhibits clathrin-mediated endocytosis, whereas a later study in A431 cells 
demonstrates that sequestration of actin monomers by actin-binding proteins or 
disruption of actin filaments by drugs also inhibits the rate of endocytosis (Lamaze et 
al. 1997). It has been reported that glucocorticoids can stabilize actin filaments 
(Castellino et al. 1992). Pretreatment of AtT20 cells with DEX (100 nM) (at least 2 h) 
partially prevents drug-induced disruption of actin filaments. Furthermore, exposure 
of human pneumocytes type II cells to DEX for 12 h significantly thickens actin 
bundles (Castelllino et al. 1992). It is not sure whether glucocorticoids have similar 
effect in corticotrope cells, and if it were, how this would affect the rate of receptor 
internalization.  However, given that the findings by Castellino et al. (1992) and 
Lamaze et al. (1996), in the present study, the possibility that cortisol perifusion 
affects AVP-induced desensitization by inhibiting V1b receptor internalization could 
not be excluded. 
   
 It has been suggested that intermediate steroid feedback occurs under physiological 
conditions when circulating glucocorticoids increase in response to moderate stress 
(Keller-Wood & Dallman 1984). In addition, AVP is implicated to play a major role 
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in maintaining pituitary responsiveness despite of elevated plasma steroids during 
stress adaptation (Aguilera & Rabadan-Diehl 2000).  The present findings may 
provide a relevant mechanism for AVP regulating of ACTH secretion during stress: 
the circulating glucocorticoids may contribute to maintain ACTH responsiveness by 
AVP through partially preventing desensitization of the ACTH response to AVP. 
 
In summary, data from present study have demonstrated that cortisol significantly 
reduces the magnitude of desensitization of the ACTH response to AVP in perifused 
ovine anterior pituitary cells. However, no evidence from this study indicates the 
effect of cortisol is dose-dependent. In view of the relatively low concentrations of 
cortisol used in the present study, these in vitro findings may be relevant in vivo also. 
4.3 Influence of CRH and Cortisol in Combination on Desensitization 
of the ACTH Response to AVP 
The current study investigated the effect of combined CRH and cortisol on AVP-
induced ACTH desensitization. In the presence of CRH (0.2 nM) and cortisol (100 
nM) in combination, the magnitude of desensitization of the ACTH response to AVP 
was significantly enhanced, compared with the magnitude of this desensitization in 
the absence of combined CRH and cortisol.  
 
As discussed in Section 4.1, factors that influence the AVP desensitization process are 
likely to act through modulating V1b receptor phosphorylation and /or internalization. 
Since GRKs may be involved in V1b receptor phosphorylation, regulation of GRK 
activity could influence the desensitization process. As mentioned before, cortisol 
administration may decrease GRK activation through stimulation of CaM mRNA and 
protein levels (Shipston 1995; Sallese et al. 2000).  However, the increase of CaM 
mRNA by DEX treatment in mouse AtT20 cells was blocked by simultaneous 
addition of CRH (Shipston & Antoni 1992b). This suggests that CRH can counteract 
the effect of cortisol on GRK activity. In addition to this, CRH alone is able to 
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enhance AVP-induced ACTH desensitization, which is possibly through PKA-
dependent phosphorylation of GRKs (see Section 4.1). It is likely that CRH not only 
blocks the inhibitory effect of cortisol on GRK activity, but also enhances GRK 
activation via other mechanisms.  It has also been suggested that CRH or cortisol 
alone may affect receptor endocytosis (see Section 4.1 & 4.2; Mogenson et al. 1988; 
Castellino et al. 1992; Kaksonen et al. 2006). However, it is difficult to predict how 
CRH and cortisol in combination influences the internalization of V1b receptor based 
on these previous findings. Overall, the effect of combined CRH and cortisol on AVP-
induced ACTH desensitization appears to be mediated by complex interactions 
between these hormones. 
  
It has previously been demonstrated that CRH can protect the ACTH secretory 
response to AVP against cortisol inhibition in perifused horse anterior pituitary cells 
(Evans et al. 1996). This effect of CRH was also observed in the present study: the 
response to the first AVP pulse was similar in either the absence or the presence of 
CRH and cortisol in combination. Some transcription factors, such as c-fos, have been 
shown to interfere with glucocorticoid-induced gene transcription (Diamond et al. 
1990). In rat anterior pituitary cells, CRH application activates c-fos, helps to prevent 
the inhibitory effect of DEX on proopiomelanocortin gene transcription (Autelitano & 
Sheppard 1993). Furthermore, the blockade of DEX inhibition by CRH was impaired 
by the presence of puromycin, suggesting that this effect of CRH depends on the rapid 
synthesis of c-fos (Autelitano & Sheppard 1993). 
 
 CRH may also prevent the actions of glucocorticoids through modulating GR 
activity. A recent report showed that injection of a CRH receptor antagonist into 
normal rats resulted in a significant increase in GR binding to endogenous 
corticosterone in the anterior pituitary (Hügin-Flores et al. 2003), suggesting that 
CRH can regulate GR activity. Furthermore, purified rat liver GRs can be 
phosphorylated by PKA, and this phosphorylation may inactivate GRs by keeping 
them in cytosol (Singh & Moudgil 1985). Since CRH application stimulates cAMP 
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accumulation, GRs in pituitary gland might undergo a similar phosphorylation to that 
seen in rat liver cells, thereby resulting in loss of glucocorticoid action. 
  
Alternatively, as pointed out by Antoni (1993), the efficacy of glucocorticoid 
inhibition of the ACTH response is actually not reduced, since the response to AVP in 
the presence of CRH is much greater than that to AVP alone. It thus appears that, in 
the presence of CRH and cortisol in combination, the synergistic effect of CRH and 
AVP counteracts the inhibition of ACTH secretion by cortisol. 
 
The relatively high concentrations used in the present study (0.2 nM CRH & 100 nM 
cortisol) indicates that the effect of CRH and cortisol in combination on AVP-induced 
ACTH desensitization may be important in the regulation of ACTH secretion under 
stressful conditions, where circulating levels of CRH and /or cortisol are much higher 
than basal conditions. Although the precise role of this effect in the regulation of 
ACTH secretion in response to stress is not well known, it is clear that the pituitary 
responsiveness during stress is regulated not only by the direct actions of CRH and 
glucocorticoids on the ACTH release, but also by their indirect actions such as 
modulating the extent of AVP-induced desensitization of the ACTH response.     
 
In summary, data from the present study have demonstrated that in the presence of 
combined CRH and cortisol, desensitization of the ACTH response to AVP was 
significantly augmented. This effect of CRH and cortisol in combination resembles 
the effect of CRH alone, but contrasts with that of cortisol alone.  
4.4 Suggestions for Further Research 
The present study explored the influence of hormonal interaction on AVP-induced 
ACTH desensitization in perifused ovine anterior pituitary cells. Either CRH alone or 
CRH and cortisol in combination enhanced the magnitude of desensitization of the 
ACTH response to AVP. In contrast, continuous perifusion of cortisol alone reduced 
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the magnitude of this desensitization. However, mechanisms underlying these are not 
well understood. 
 
With PKC and casein kinase 1α being not involved in V1b receptor phosphorylation 
(Hassan & Mason 2005), it is not known which kinase(s) is responsible for this 
receptor phosphorylation during the desensitization process. This makes it very 
difficult to further characterize this process and investigate possible factors which 
contribute to or affect this process. An investigation whether GRK(s) is involved in 
desensitization of the ACTH response to AVP is currently in progress in our 
laboratory using antisence oligonucleotides to inhibit expression of GRKs. 
 
While V1b receptor internalization has been shown to be important in AVP 
desensitization (Hassan & Mason 2005), it is unsure whether the effect of CRH or 
cortisol on this desensitization process is dependent on changes in the rate of receptor 
internalization. More information about the effects of CRH and/or cortisol treatment 
on V1b receptor internalization in the pituitary gland is required to elucidate the 
mechanisms involved in the regulation of AVP-induced ACTH desensitization. 
 
Mechanisms involved in glucocorticoid feedback vary with the time of steroid 
application (Keller-Wood & Dallman 1984). In the present study, all AVP pulses 
were given between 2-5 h from the onset of cortisol perifusion. This falls into 
intermediate steroid feedback (2-10 h of steroid exposure), suggesting that the effect 
of glucocorticoids on ACTH secretion requires new protein synthesis (Keller-Wood & 
Dallman 1984). In our laboratory, a project is currently being conducted to investigate 
whether protein synthesis induced by cortisol exposure influences the AVP 
desensitization process. This is done using protocols similar to that used in Section 
3.2, but by simultaneous perifusion with a protein synthesis inhibitor, cycloheximide 
and cortisol together. This enables us to see the effect of inhibition of protein 
synthesis on AVP-induced desensitization of the ACTH response. In future, it may be 
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of interest to see whether changing the time of the onset of cortisol perifusion will 
result in different effect of cortisol on desensitization of the ACTH response to AVP. 
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APPENDIX A 
Materials 
 
[Arg8]-vasopressin, acetate salt Sigma Chemical Co. 
0.22 µm polyethersulfone filter Millipore Corporation, Bedford MA 
0.45 µm mixed cellulose filter Millipore Corporation, Bedford MA 
Biogel P-2 Biorad Laboratories, Hercules CA 
Bovine γ-globulin Sigma Chemical Co. 
CaCl2.2H2O Reidel-De Haen AG, Hannover, Germany 
Chloramine T  BDH Chemical Ltd. 
Corticotropin-releasing hormone Sigma Chemical Co. 
D-glucose BDH Laboratory Supplies  
DME powder Sigma Chemical Co. 
HEPES Sigma–aldrich, Inc. 
Hydrocortisone Sigma–aldrich, Inc.  
KCl May and Baker Australia Ltd, West 
Footscray, Victoria, Australia 
KH2PO4 BDH Chemical Ltd. 
L-ascorbic acid Sigma Chemical Co. 
L-glutamate Sigma Chemical Co. 
Non-essential amino acids Sigma Chemical Co. 
MgSO4.7H2O BDH Chemical Ltd. 
Na2HPO4 BDH Laboratory Supplies 
NaCl BDH Laboratory Supplies 
NaHCO3 BDH Laboratory Supplies 
NaN3 BDH Chemical Ltd. 
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NaOH BDH Laboratory Supplies 
Newborn calf serum (NCS) Invitrogen/Life Technologies, 
Nybolt nylon gauze Seidengaze, Zurich, Switzerland 
Okadaic acid Sigma Chemical Co. 
Ovine ACTH  Dr C.H.Li, Hormone Research Laboratory, 
University of California, USA 
Penicillin G (sodium salt) Sigma–aldrich co.  
Phenol red (sodium salt) Sigma Chemical Co. 
Plastic petri dishes Labserv, Auckland 
Polyethylene glycol 6000 Scharlau Chemie, Spain 
Sephadex G-25 fine Sigma Chemical Co. 
Sodium metabisulphite BDH Chemical Ltd. 
Streptomycin sulphate Sigma Chemical Co. 
Triton X-100 Sigma Chemical Co. 
Trypan blue BDH Chemical Ltd. 
Type II collagenase Sigma Chemical Co 
. 
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APPENDIX B 
SOLUTIONS 
 
1. Cell preparation  
 
1.1 Dispersing Buffer (DB) 
This solution was made up by dissolving the following reagents in deionised, 
distilled water (ddH2O) to give the final concentrations shown below. Usually 5 L 
was made up for each time. After all reagents completely dissolved, the pH was 
adjusted to 7.3 using concentrated NaOH or HCl. In the laminar flow hood, the 
solution was sterilised by pumping filtration through 0.22 µm polyethersulfone 
filter, and then was stored at 4ºC. 
NaCl                                                      137 mM 
KCl 5 mM 
N-[2-hydroxyehtyl]piperazine- 
N’-2-ethanesulfonic acid (HEPES) 25 mM 
D-Glucose 10 mM 
Phenol red (sodium salt)  53 nM 
Penicillin G                                            100 U/ml 
Streptomycin sulphate                           100 µg/ml 
Amphotericin B 0.25 µg/ml 
 
1.2 Dulbecco’s modified eagles medium (DME) 
Usually 1 L was made up for each time. One bottle of commercially prepared, 
powdered medium was dissolved in ddH2O in a 1 L volumetric flask. The 
quantities and final concentrations of the other reagents were shown below. After 
all the reagents dissolved, the solution was made up to 1 L with ddH2O, and the 
pH was adjusted to 7.1. The medium was then sterilized by filtering through 0.45 
  Appendix B 
 79 
µm MCE filter in the flow hood, and stored at 4ºC for up to two months. 10% 
newborn calf serum was added before use. If the solution was 4 weeks old, fresh 
L-glutamate was also added (final concentration: 2 mM) before use in the cell 
culture. 
NaHCO3  44 mM 
HEPES 25 mM 
Non-essential amino acids 1.0 ml 
Phenol red (sodium salt) 42 nM 
Penicillin G 100 U/ml 
Streptomycin sulphate                           100 µg/ml 
Amphotericin B 0.25 µg/ml 
 
2. Perifusion experiment 
 
2.1 Stock solutions for Krebs ringer (KR) 
Five stock solutions were made up and stored for late KR preparation. The 
reagents given below were dissolved in ddH2O to give the concentrations shown. 
Usually 250 ml NaCl stock solution and 100 ml for each of other stock solutions 
were made up for each time. These stocks were stored at 4ºC. 
NaCl                                                       5 M 
KCl 0.47 M 
CaCl2.2H2O 0.25 M 
KH2PO4 0.12 M 
MgSO4.7H2O 0.12 M 
 
2.2 Krebs Ringer (KR) 
Usually 5 L or 2 L was made up for each time. The reagents listed below (Stock-
containing reagents were dissolved by adding the appropriate volumes of stock 
solution in ddH2O) were dissolved in ddH2O to give the concentrations shown. 
After the pH was adjusted to 7.3 the solution was filter-sterilized as either for DB 
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(5 L made up) or for DME (2 L made up), then stored at 4ºC. On the day of 
perifusion, 0.05% ATC and 0.005% L-ascorbate were added to the solution to 
make up KR/ATC (Check the pH was between 7.3-7.4 after the addition of ATC 
and ascorbate). KR/ATC was the basic perifusion medium used in this research. 
NaCl                                                      125 mM 
KCl 4.7 mM 
CaCl2.2H2O 2.5 mM 
KH2PO4 1.2 mM 
MgSO4.7H2O                                        1.2 mM 
NaHCO3  3.6 mM 
HEPES 25 mM 
D-Glucose 10 mM 
Phenol red (sodium salt)  3.5 nM 
Penicillin G                                            100 U/ml 
Streptomycin sulphate                           100 µg/ml 
Amphotericin B 0.25 µg/ml 
 
2.3 KCl (100 mM) Krebs Ringer 
This solution was produced similarly with the preparation of KR, except that the 
final concentrations of NaCl and KCl were changed. Besides, the pure KCl 
powder rather than KCl stock solution was dissolved in ddH2O to give the 
expected concentration. After the pH was adjusted to 7.3, the solution was filter-
sterilized through 0.22 µm filter and stored at 4ºC. 
NaCl                                                      85 mM 
KCl 99 mM 
CaCl2.2H2O 2.5 mM 
KH2PO4 1.2 mM 
MgSO4.7H2O 1.2 mM 
NaHCO3  3.6 mM 
HEPES 25 mM 
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D-Glucose 10 mM 
Phenol red (sodium salt)  3.5 nM 
Penicillin G                                            100 U/ml 
Streptomycin sulphate                           100 µg/ml 
Amphotericin B 0.25 µg/ml 
 
2.4 Sephadex and Biogel preparation 
Weigh out the reagents into small sterile glass bottles before hand (Sephadex ≥0.8 
g, Biogel≥0.4g). Add some KR in to swell the bead on the day before perifusion. 
Store at 4ºC. Change KR once on that day. On the day of perifusion, change KR 
once, allowing the beads to settle down. Then adjust the height of gel and the KR 
to a ratio of 2:1 for use in the perifusion experiment.  
 
2.5 Preparation of treatment solutions 
Treatment solutions (solutions containing hormones) were prepared by diluting a 
stock solution with KR/ATC (or KR/ATC containing another hormone) to give 
the desired concentration. Stock solutions of AVP (20 µM) and CRH (1 µM) were 
prepared by Dr. Drusilla Mason, and stored at -80 ºC. Stock solution of cortisol (1 
mM) was prepared by dissolving hydrocortisone in 95% ethanol, and stored at -
20ºC. On the day of experiment, appropriate volumes of stock solutions were 
thawed and diluted in KR/ATC to make up the treatment solutions at required 
concentrations. 
 
3. Radioimmunoassay Solutions  
 
3.1 Phosphate buffer stock (0.5 M)  
This solution was used as a stock solution for preparing other solutions used in 
RIA. The reagents listed below were dissolved in ddH2O and made up to 1 L in a 
volumetric flask. The buffer was stored frozen until use. 
KH2PO4 (anhydrous)       18 g 
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Na2HPO4 (anhydrous)            52.3 g 
Ethylenediamine tetraacetic acid  
(disodium salt; Na2EDTA) 0.1 g 
NaN3    2 g 
 
3.2 Phosphate/ATC buffer (P/ATC) 
Usually 1 L was made up for each time. 0.5 M phosphate buffer was diluted (1/10) 
with ddH2O, and appropriate amount of ATC was added according to 1 g/L. After 
the pH was adjusted to 7.4, the solution was stored frozen until use. 
 
3.3 Polyethylene Glycol solution (PEG) 
18% PEG solution was prepared according to protocols shown below and stored at 
room temperature. 
PEG6000 (Scharlau)  360 g 
NaCl    11.7 g 
0.5 M phosphate buffer  210 g 
ddH2O    1500 ml 
Triton X-100   2 ml 
 
3.4 γ-globulin 
This solution was prepared by dissolving γ-globulin in P/ATC solution to give a 
final concentration of 12 g/L (1.2%). It was stored at -20ºC and usually used 
within one month. 
